

REPRODUCTION QUALITY NOTICE

This document is the best quality available. The copy furnished to DTIC contained pages that may have the following quality problems:

- Pages smaller or larger than normal.
- Pages with background color or light colored printing.
- Pages with small type or poor printing; and or
- Pages with continuous tone material or color photographs.

Due to various output media available these conditions may or may not cause poor legibility in the microfiche or hardcopy output you receive.

If this block is checked, the copy furnished to DTIC contained pages with color printing, that when reproduced in Black and White, may change detail of the original copy.

REPORT DOCUMENTATION	PAGE	READ INSTRUCTIONS
		BEFORE COMPLETING FORM 3. RECIPIENT'S CATALOG NUMBER
. TITLE (and Subtitie)		S. TYPE OF REPORT & PERIOD COVERED
Develop a Biomedical Database on th	he Medical	Annual
Aspects of Chemical Defense		Vol. 2 6. PERFORMING ORG. REPORT NUMBER
		6. PERFORMING ORG. REPORT NUMBER
AUTHOR(.)		8. CONTRACT OR GRANT NUMBER(*)
Lawrence A. Landry		DAMD 17-80-C-0136
PERFORMING OR JANIZATION NAME AND ADDRESS		10. PROGRAM ELEMENT. PROJECT, TASK
Associate Consultants, Inc.		AREA & WORK UNIT NUMBERS
1701 K Street, N. W. Washington, D.C. 20006		62734A.3M162734875.AD.373
1. CONTROLLING OFFICE NAME AND ADDRESS		12. REPORT DATE
US Army Medical Research and Develo	nment Command	Oct. 1981
Fort Detrick, Frederick, MD 21701 - A		13. NUMBER OF PAGES
4. MONITORING AGENCY NAME & ADDRESS(I different	-	144 15. SECURITY CLASS. (of this report)
		unclassified
		15e. DECLASSIFICATION/DOWNGRADING SCHEDULE
		SCHEDULE
Approved for public release; distri	bution unlimited	
Approved for public release; distri 7. DISTRIBUTION STATEMENT (of the ebetrect entered (
7. DISTRIBUTION STATEMENT (of the abetract entered i		
7. DISTRIBUTION STATEMENT (of the abetract entered i		
7. DISTRIBUTION STATEMENT (of the abetract entered i		
7. DISTRIBUTION STATEMENT (of the abetract entered i	n Block 20, If different from	
7. DISTRIBUTION STATEMENT (of the abetract entered i 8. SUPPLEMENTARY NOTES	n Block 20, If different from	
7. DISTRIBUTION STATEMENT (of the abetract entered i 8. SUPPLEMENTARY NOTES	n Block 20, If different from	
7. DISTRIBUTION STATEMENT (of the abetract entered i 8. SUPPLEMENTARY NOTES	n Block 20, If different from	
7. DISTRIBUTION STATEMENT (of the abetract entered i 8. SUPPLEMENTARY NOTES	n Block 20, if different from	
7. DISTRIBUTION STATEMENT (of the abetract entered i 8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse side if necessary end	n Block 20, if different from	
7. DISTRIBUTION STATEMENT (of the abetract entered i 8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse side if necessary end	n Block 20, if different from	
7. DISTRIBUTION STATEMENT (of the abetract entered i 8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse side if necessary end	n Block 20, if different from	
7. DISTRIBUTION STATEMENT (of the abetract entered i 8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse side if necessary end	n Block 20, if different from	
7. DISTRIBUTION STATEMENT (of the abetract entered i 8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse side if necessary end	n Block 20, if different from	
7. DISTRIBUTION STATEMENT (of the abetract entered i 8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse side if necessary end	n Block 20, If different from	

APPENDICES

V

`....

うちちちちろうちちちちちちちち Ι

I

L

Appendix A. Guidelines for Abstractors

- Computerization Reports from Gill Associates, Inc з.
- C. Ten Sample Unit Records

D. Print-Out of Sample Thesaurus

CHEMICAL AGENT RETRIEVAL SYSTEM

A Comparative Analysis of Minicomputers and Large Scale Computers

Report to:

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND DEPARTMENT OF THE ARMY

Prepared for:

i.

Ū

ASSOCIATE CONSULTANTS, INC.

GILL ASSOCIATES, INC. MANAGEMENT CONSULTANTS

April, 1981

TABLE OF CONTENTS

I.	Introduction	1
II.	Examination and Assessment	4
III.	Range of Options	12
IV.	Assimilation of Minicomputer Technolocy	14
v.	Guidelines	17
VI.	Summary	19

Ţ

:

Γ,

 \int

Π

Gill Associates. Inc.

I. INTRODUCTION

This report satisfies a special request made by USAMRDC personnel for a discussion paper on the advantages and disadvantages of minicomputers versus large-scale machines. The request was made, and subsequent analysis performed, in order to help determine the best computer architecture and philosophy to be used in Physe I and Phase II implementation of the chemical agent information retrieval system.

The document addresses some of the essential differences between large machines and minicomputers as they relate to the characteristics of the applications to which they are to be applied. With this information, USAMRDC personnel (responsible for establishing information systems and computer policy) will have both justification for the use of minis in particular situations and a framework for selecting the proper data processing environment, large machine or mini, for implementing the chemical data base.

The trend toward centralization of computing was set in motion in the early 1970's when analysts found that a few large computers could do the work of several small or medium ones for less money. A perennial lack of qualified computer specialists reinforced this significant cost benefit, and the emergence of data base technology that enabled report integration on its operation further fueled the flames of centralization.

More recently, however, evidence suggests that this path is not necessarily a good one. Service levels seems to be deteriorating: users complain that data centers are lethargic and nonresponsive, and

1:

Gill Associates, Inc.

A CANADA CANA

centralization of computer facilities all too often runs against the decentralized operations preferred by many organizations. In addition, there have been difficult administrative problems in forging formal coordination and control policy for the centralized computer organization. Some of these problems could be viewed as ransitional; others are more fundamental. For example, in order for centralized computing to be effective, executive management must be willing to endorse and enforce standardized data processing project development.

As a consequence of these administrative and organizational difficulties, a burdening question confronts management: Are the measurable economic benefits of centralized computing worth the side effects? Developments in minicomputer technology have dramatically changed the economic and organizational variables. Today winicomputers are available for a fraction of the cost of large computers and can be operated with less specialized support than the large ones require. This not to imply that minis are going to replace large mainframes in the near future. The implication is, however, that technology has matured to the point where the costs of using a mini for certain data processing jobs compare favorably with using a portion of the capacity of a large machine.

In order to take advantage of minicomputer technology, management must first understand its status and its potential, since it is management that must provide the initiative. the support, and the guidance for its implementation. Three areas of concern are addressed in promoting this understanding:

 Examination and assessment of the capabilities of minis as opposed to those of more familiar medium and large computers,

2

Gill Associates. Inc.

- Illustration of a range of options for effective use of the new technology, and
- Assimilation of mini technology into an organization outlining management action guidelines.

3

.

; ; ;

-

Gill Associates. Inc.

A STATE AND A STATE

II. EXAMINATION AND ASSESSMENT

A minicomputer cost approximately \$50,000 for a typical business application and can perform a amount of the work of computers costing \$2,000,000. In Table 1, the key architecture and design characteristics of large, madium, and small computers have been outlined alongwith and assessment of the managerial significance of these differences. Data provided in this table are based upon industry averages and a representative group of computers from each category.

Two general observations can be drawn from this exhibit. First, through the minicomputer is not as "powerful" as the large or medium computer, it is suprisingly close, given the substantial price differentials. One reason for this closeness is that it has been possible to utilize new hardware technology considerably earlier in minis than in large machines because there is a smaller investment in hardware and software design for a mini. Consequently, a vendor can produce and integrate a new mini into his line much more rapidly than a large computer.

Since an important characteristic of new technology in the computer area has been rapidly decreasing cost, the price for a given amount of power in minis has been lowered consistently and quite rapidly. For example, in 1965 it cost \$25,000 to purchase a machine with 4,096 16-bit words and a 2-microsecond cycle time. Because of advances made in microtechnology, by 1974 it cost only \$1,990 to purchase a machine with these capabilities.

1...

Gill Associates, Inc.

The second general observation concerns software. Large machine software is more advanced, and thus applications with substantial multiprogramming or shared multipurpose data bases require a large or medium machine. However, minicomputer manufacturers have recognized that one of their next big markets is the end-user business application, and so over the past two years they have begun to make substantial investments in software developments. As a result, it is now possible to use minicomputers as easily as it is large machines for many business applications.

In fact, it seems that the industry is now moving into an evolutionary stage where what is needed is increased investment in people for application programs and software development — not breakthrough in technology. This will become clear as the services that minis can provide, and the steps management must consider in attempting to assimilate them into the organization, are discussed.

5

のためのないであっていたい

A DA BILL

Table 1. Technical comparison of large, medium and minicomputers

.

. •

States of the second states of the

*

•••

.

•

۰.

.

Ì

Π

KEY COMPUTER ARCH- ITECTURE CHAR- ACTERISTICS	LARGE COMPUTER	NED I UN	MINICOMPUTERS	EFFECT Minicomputer vs. medium and large computers	SIGNIFICANCE Minicomputer vs. medium and large computers
ILA ROVARE					
Word length	32 bits (a bit is equivalent to a binary digit)	32 bits	l6 bits	Size of readily ad- dressable program or data areas is re- stricted. Instruc- tion repertoire is smaller.	Efficiently implement- ed higher level lan- guages are hard to provide, thus only a few exist. Large ap- aplications execute less efficiently and ace harder to program.
Maximum memory sizo	8,400,000 bytes (a byte consists of 0 bits which provides enough binary digits to repre- sent one numeric or alphabetic character)	524,000 bytes	262,000 bytes	Multiprogramming (the ability to execute programs simultane- ously) is restricted. Substantial manipula- tion of large arrays of data is restricted.	The multiprogramming limitation is not significant, since minis are relatively inexpensive and can thus be dedicated to one or a few applica- tions.
Data capacity: Memory path (width of the link between between the main memory and central processor)	64 bits	16 bits	16 bits	Execution is less efficient.	The data capacity architecture of the large computer makes it more effective for large data processing demands in a multipro-

The second second

The mini is restricted to applications requiring substantial proccessing activity, such pares with the medium computer's in a dedicated data processing gramming environment. The mini's power comenvironment, insofar as data capagity is activity is not Minicomputer vs. medium & large SIGNIFICANCE concerned. computers Instruction execution execution and I/O data Simultaneous transfer of data from multiple restricted (compared with large computer. overlap of activity Overlap of program of I/O devires are stricted (compared is slover compared I/O devices is re-Configuration and Minicomputer vs. with the large medium & large transfer is restricted. computer). computers RFFECT 2, 360,000 bytes/second MINICOMPUTER nanosecond3 None 300 One 2,400,000 bytes/second nanoseconds COMPUTER MEDIUM A few None 275 output (1/0) channels & the central procesdata to and from main neously transferring (as many as 3 Input/ sor can be simulta-1 billionth of a (1 nanosecond = LARGE COMPUTER 80 nanoseconds bytes/second 16,000,000 memory) second 4-way Many (the rate that data Data Capacity (cont KEY COMPUTER ARCH-(ability to simulmore than one part Number of channels can be transferred (how fast instruc-(chan ls operate over all channels Central processor tions can be cartaneously access I/O channel data the I/U devices) unit cycle time of main memory) to main memory) I'TEC'TURE CHARarchitecture: Interleaving ACTERIS' TICS F.Uce3sor ried out)

~ ı.

...

1

Table 1. (cont'd)

Table 1. (cont'd)

۰,

Britanikerssterne -

ļ

• •

the state of plantageners in sec

٦j

KEY COMPUTER ARCH- ITECTURE CHAR- ACTERISTICS	LARGE COMPUTER	MEDIUM Computer	MINICOMPUTERS	EFF.CT Minicomputer vs. medium and large computers	SIGNIFICANCE Minicomputer vs. medium and large computers
HARDWARE (cont'd)					
Memory cycle (how fast instruc- tions or data can be retrieved from main memory; it should be consid- ered together with the width of the memory path)	480 nanoseconds	800 nanoseconds	850 nanoseconds	Instruction and data transfer to memory 18 somewhat slower (compared with large computer).	typical of business applications.
Number of registers (an indication of more sophisticated programming)	Many	Hany	Ralatively few	System software dev- elopment is limited.	
Number of basic instructions	Approximately 150	Approximately 140	Approximately 80	Execution is less efficient.	
SOFTWARE					
Operating systems: Batch (applications prog- grams are submitted to computer in selfcontained units	Multiprogramming (batch applications are run simultaneously)	Multiprogram- ming	Multiprogram- ming (2 pro- grams only)	Computer system resources can be sufficiently utilized	Systems software for the large and medium computer is complex and designed for mul- tiple tasks in order
with no strict tim- ing requirements)					to share expensive resources, this is not

14.14

シャ わちしい

Ī

Table 1. (cont'd)

KEY COMPUTER ARCH- ITEXTURE CHAR- ACTERISTICS	LARGE COMPUTER	MEDIUM Computer	HINICOMPUTERS	EFFELT Minicomputer vs. medium and large computers	SIGNIFICANCE Minicomputer vs. medium and large computers
SOFTWARE (cont'd)					
Real time (application prog- grams are called into operation in rusponse to request from I/O devices	Separate telecom- munications system added to other operating system	Same as for large computers	Telecommuni- cations Bys- tem is inte- grated with main operat- ing system	Real time on a mini is usually dedicated to one application.	necessary for the mini since it is relatively inexpensive.
Time sharing	Supported simul- taneously with other systems by addition of separate facilities	Same as for large computers	Computer must be dedicated to time sharing	Time sharing ou a mini is usually dedi- cated to support of on-line terminals.	
Data base and file management systems	Many sophisticated systems are	Many Bystems are available	A few limited systems are available	Data-base systems must be largely developed in-house	Shared multipurpose data bases are hard to implement on a mini- a significant con- straint if these are required.
Programming languages	All 8 major languages	All 8 major languages	Four major languages	COBOL is only grad- ually becoming avail- able for some minis, which is a signific- ant limitation for companies using COBOL as a standard language.	Language for some applications may not be perfectly appropri- ate, but this distinc- tion is not critical since there are enough languages available for minis.

Table 1. (cont'd)

•--

1

. . .

; j

KRY COMPUTER ARCII- ITECTURE CIIAR- ACTERISTICS	LARGE COMPUTER	MEDIUM Computer	MINICOMPUTERS	EFFECT Minicomputer vs. medium and large computers	SIGMIFICANCE Minicomputer vs. medium and large computers
SOFTWARE (cont'd)					
Program development aids	Hany	Hany	Limited	Programming effic- iency is inhibited.	More highly skilled applications program- mers are required.
(e.g., debugging aids, checkout compliers)					
Application packages (e.g., payroll, bill of materials, models)	Thous ands	Thousands	llundreds	Users must program more applications in-house.	More cost is involved in programming, if packages available for large or medium machines.
ADDITIONAL CONSIDERATIONS					
Reliability	utgh	HIgh	Very high, time to fix is brief be- cause of rel- ative sim- plicity	The mini is likely to be more reliable, but the distinction is unlikely to be important for most applications.	Reliability and vendor support must be con- sidered together.
Vendor support	Outstanding	Outstanding	Good	Caveat emptor applies to mini somewhat.	

....

Table 1. (cont'd)

Ĩ

E

KEY COMPUTER ARCH- ITECTURE CHAR- ACTERISTICS	LARGE COMPUTER	MEDIUM COMPUTER	MINICOMPUTERS	EFFECT Minicomputer vs. medium and large computers	SIGNIFLCANCE Minicomputer vs. medium and large computers
ADDITIONAL CONSIDERATION					
Purchase cost	Millions of dollars	Hurdreds of thousands of dollars	Tens of thousands of dollars	Minis are substan- tially cheaper	Purchase and opera- tional cost are the most significant
Operating requirements	Considerable amount of specially prepared space and air condi- tioning, operators and well-trained systems program- mers required	Same as for large computers	One opwrator per shift, no special site preparation, good systems programmers required	Operational costs are much lower.	advantages minis have over large and medium computers.

...


Source: EDP Solutions (Datapro Research Corporation)

1.1

III. RANGE OF OPTIONS

Options for using a mini range from enhancing the service level of the data center to replacing the center entirely. Thus the options can first be thought of as being arrayed along the links between the actual user and the central computer. Second, since minis are most often devoted to just one application and are typically located near the user, this same arraying of options can also be thought of as ranging from centralized to decentralized control of the organization's EDP resources.

The relationship between these two concepts is shown in Figure 1. For disussion purposes, four basic options, ranging from using no minis to using only minis have been listed. Of course, an organization can use minis in more than one way, since these options are not mutually exclusive.



 \prod

- Option 1 represents companies that do not use minis at all. An important issue to be raised is operational effectiveness of using one large computer for all applications. In making the decision, a company should place considerable weight on the value of separate operations for cn-line and batch applications-particularly in a system that does not already have on-line applications.
- Option 2 covers not only companies that use minis as frontends, that is, minis that handle communications between terminals and central computers, but those using other combinations of minis and large machines in computing networks as well. The idea is to use mini as the front-end of the central computer, where it can handle communications with terminals and do additional processing otherwise done on the central computer. The minicomputer could thus lower the computing load on the main machine, thereby making it available for more complex processing for which it is better suited.
- Option 3 applies to those organization in which minis handle independent applications and require no active link to the central computer. In this case, however, the mini and large machines may interchange data on a periodic basis, for instance, nightly. A distinct advantage of this option is that the performance level of mainframe suffers no deterioration as new and independent applications are added to the system. These applications can be readily absorbed by the minis.
- Option 4 represents companies using only minis. It includes those with departmental minicomputers that are tied together in networks with telephone lines to permit sharing of data and programs. This lends itself to organizations fostering a decentralized operating philosophy. The disirability of user control i promoted with this arrangement. Where applicable, some central coordination of computing may result in a degree of standardization of computer operation or software and may contribute to organizational effectiveness.

13

Π

Gill Associates. Inc.

IV. ASSIMILATION OF MINICOMPUTER TECHNOLOGY

The use of minis is not necessarily an either/or proposition. Instead, management needs to determine how minis can most effectively be integrated into the overall data processing system of an organization. This determination is best made by first carrying out a highlevel design for the application. Table 1 provides such a design framework to use in examining the characteristics of a mini that limit its power with respect to a large or medium machine. In particular, the primary limitations occur when the application requires either-a substantial amount of processing or the establishment of a complex data base common to multiple applications.

After this analysis is completed and has shown a minicomputer to be feasible, the decision to use a mini, medium, or large computer requires a qualitative weighing of three factors:

- A. Economics
- B. User Control
- C. Operation Effectiveness

A. Econchics

Cost is perhaps the most compelling justification for using or not using a mini. There are three components of cost: software development, hardware, and operations. Software development costs for large machines and minis will generally be comparable, but the numberous commercial software packages available for large computers will often justify using a large computer for an application. In analyzing the hardware and operating costs for the large machine, the command must decide whether full costing would charge the application for all resources that it uses directly plus a proportionate share of all other resources in the system that are shared,

Gill Associates, Inc.

such as people and space. Direct costing charges the new appliacation only for the required incremental resources, such as direct use of the central processing unit and peripheral equipment. If existing computer facilities are idle because of underutilization of large machine, arguments can be made for incremental costing of a new application.

Although it may be desirable to use direct costing in some situations, it is important to recognize that there will be pressure from full-cost users to relegate direct-cost users to lower-priority computer time and to suspend them during periods of high load on the large machine. In addition, as the computer needs of a command grow, it may require a larger machine. The direct-cost user will have contributed to making the load heavy enough to justify a new machine and may then have to be charged full instead of direct costs. Thus using direct costing has some pitfalls and must be viewed cautiously.

B. USER CONTROL

The mini allows the user to be independent of other programs on the main computer. In addition, the user of the mini is free from concern about the computer center's need to keep its machine operational and upgrade its capabilities to meet increasing loads. These issues may arise when some users of the large machine have a heavy, high priority load that interferes with the needs of other users. This situation is particularly frustrating when one division is particularly frustrating when one division is particularly frustrating when one division controls the central computer. (This same problem occurs for small or medium-sized organizations that utilize a service bureau.) The user with his own mini will not suffer from interruptions of this type. Independence is also particularly useful for a user when there are response time constraints, since response will be fully under the user's control.

15

Gill Associates, Inc.

C. OPERATIONAL EFFECTIVENESS

For substantially decentralized operations, today's economical mini may be more practical and far less disruptive than larger machines for inhouse data processing. The mini can help relieve the complexity of the operational load on the central computer. With this simpler enviornment (particularly with on-line systems), the data processing center will require less systems programming talent, which may be shifted to serve users' needs directly.

Gill Associates, Inc.

۰.

Ţ

V. <u>GUIDELINES</u>

Minicomputer technology has now matured to the stage where managemert can harness its economic and organization potential. Management's responsibility is to develop an understanding of the appropriate way to integrate minicomputers into the organization. Each should carefully assess its data processing system in terms of where it is going and how, and it should inspect the opportunities for taking advantage of minicomputers.

The data processing staff should build a good understanding of the use and programming of minis. Over a three-year horizon this understanding should evolve so that all computer designers and programmers are equally comfortable using large or small machines. Thus for the long run it is inappropriate to separate the computer staff into minicomputer and large machine programmers. However, in order to get this learning started, it will be necessary to build an understanding of minis in the computer staff, and such a separation may initially be necessary.

To provide leadership to engender an appropriate environment and policy superstructure for incorporating minicomputer technology, top management should take the following actions:

- Direct the EDP manager to acquire and build minicomputer technology capability by integrating technical systems and applications expertise into the current staff.
- Establish a policy to include minicomputer options among alternatives for all new major applications.
- Look for an opportunity to use a mini for the computing needs of a small, independent division, for instance, one that refuses to perticipate in the central computer utility.

Gill Associates. Inc.

This could also be an opportunity for the entire command to gain valuable experience.

• Establish a central function to study and promulgate minicomputer standards for hardware, software, applications development, and data bases. This is a very important function to keep under control when computer systems are being decentralized.

Gill Associates, Inc.

and the second second second

Sec. 1

VI. SUMMARY

Although the cost of mini computers itself is low, the total computing facility is not only the CPU. The peripheral devices for the mini computers are still costly. Also, the cost of software supplied by the manufacturer and that to be developed by the user has to be considered. Hence, when the cost comparison between a minicomputer and mainframe alternative is to be done, the comparison must include the total cost The comparison should include not only the dollar figure, but non-tangibles such as dependability and "after-sales" customer service from the supplier as well. In general, customer service has been better from manufacturers of mainframes.

In conclusion the decision to use minicomputers, or mainframes or a combination of these will depend on the particular application under consideration. Certain applications will be definitely suited for minicomputers; while for others, mainframes will be the certain solution.

In light of the chemical information retrieval system the volume of data anticipated for Phase II implementation essentially dictates the use of a large machine because of the current storage limitations of peripherals (specially disk units) associated with minicomputers. In addition large machines would better allow for system expandibility. In the more likely event that new or related applications are desired, these machines could accommodate future enhancements with less regard to technical questions of space and specific programmer talent. There will be many problems or applications where whether to use mini, mainframe, or a combination of these may not be so obvious. In such situations, a thorough study of present requirements and future

19

Gill Associates. Inc.

がありまたがあると

requirements along with what is available and what is going to be available should be made before making the final choice.

٠•.

1

1.

Ī

Ī.

--

•

•

.

1

Chemical Agent Retrieval System Procedures for Completing the Unit Record Coding Form

....

FIELD NAME

Action Code

PROCEDURE

Circle the code designating the status of the form to be processed as follows:

To add a new record to the date base:

- 1. Circle Action Code 1
- 2. Enter Accession Number
- 3. Fill in all applicable data fields

To change/update a record in the database:

- 1. Circle Action Code 2
- 2. Enter Accession Number
- 3. Complete only the field to be changed

To delete a record from the database:

1. Circle Action Code 3

to each unit record.

bution of the report.

L

- Limited

UL - Unlimited

2. Enter Accession Number

Accession Number

Distribution Status

Security Classification

· · · · · ·

US - U.S. NUS - Non-U.S. M - Military

Enter the unique identifying number assigned

Enter the code designation for the distri-

NM - Non-military

Enter the letter code that designates the security classification assigned to each document. The code designation are as follows:

- U Unclassified
- C Confidential
- S Secret
- R Restricted
- N NATO

Gill Associates, Inc.

2.

FIELD NAME

Country Code

Number of Fiche

Language Code

Document Type

Number of Pages

Publication Year

Volume Number

Issue Number

PROCEDURE

Look up the code designation for the country where the work or research was performed in <u>Country Code Table</u> shown in Table 1. Record the code on the coding form.

Leave field blank on forms coded for the initial creation of the database.

When the system is fully operation 1, enter the figure for the total number of fiche on which the abstract is stored.

Enter the code for the language of the article being abstracted. See Table 2 for Language Code designations.

Enter the coding for the type of source of the document. Code designations are as follows:

- J Journal
- B Book
- R Report
- P Patent
- T Translation

Enter total number of pages for the source document.

Enter the year the document was published.

For documents having a publication date of more than one year, enter the range, e.g., 1971-1972.

Enter the volume number of the source document, if applicable.

Enter the issue number of the source document, if applicable.

Gill Associates. Inc.

and the There also a

FIELD NAME

Fiche Number

Task Number

Project Number

Review

Page Range

Number of References

CAS Registry Number

Grant/Contract Number

Custodian

E

Report Number

Number of Graphics

3.

PROCEDURE

Count the number of graphics, illustrations and tables in the document being abstracted.

Enter the number in the field.

Enter the fiche number assigned to the abstract. (This will not be assigned during the initial processing for creation of the database.)

Enter the unique number identifying the task being performed.

Enter the unique project number for the project.

Enter "R" if the article is a review. Otherwise leave blank.

Enter the page range for the project.e.g., 1170 -1192 .

Count the number of references in the bibliography. Enter the number in the field.

Enter the unique report number(s) assigned to the document. A maximum of four (4) numbers can be coded.

Enter the unique numbers assigned by the Chemical Abstract Service to a chemical compound. A maximum of 30 numbers can be coded.

Enter the identifying number under which the research was funded.

Code for unpublished material only. Enter the name of the person or organization responsible for the unpublished material.

Gill Associates, Inc.

FIELD NAME

Editor

Author

Affiliation

Source Title

Performing Organization

Sponsoring Organization

4.

PROCEDURE

Enter the name(s) of the Editor of the document book or conference.

Enter the name(s) of the author of the document in last name - first name - middle initial order. A maximum of 10 authors can be coded. Separate coding fields are provided for each author.

Location/Repository Enter the name of the place where the unpublished material is being held. Enter the city name, state or country (State of U.S. location, Country for non-U.S. location)

Index Terms/Keywords Code the keywords developed from the article by the Abstractors

Enter the name of the institution where the work-was performed by the author(s). Enter

- Name of Institution - City and State or Country

Enter the name of the document- book, journal, etc. - in which the article was published.

Enter the following for the organization where the research was conducted:

- Name of Organization
- Street address (if applicable)
- City
- State or Country

Enter the following data of the organization for whom the research was performed:

- Name of Organization
- Street address (if applicable)
- City
- State or Country

Gill Associates, Inc.

A TANK A TANK

المري موادية الراجع معنا المعرفين المعرد الا

FIELD NAME

Comment

1:

PROCEDURE

Title of ArticleEnter the title of heading of the article or
documentor Documentdocument being abstracted.

Enter any special comments related to the project, such as reference to related articles.

Abstract/Digest Type the full text of the digest or abstract to be stored in the system. A maximum of 4,500 characters are allowed.

Gill Associates, Inc.

TABLE 1

· · ·

.

- -

1C 12

2572

20

10

AS

AT AU AV

AY

58

3C 30 3E

37

ag Bh

BL.

32 30

3T 3U

34

1.

11

- .-

.....

a care a

LISTING OF COUNTRY CODES

GR GT

GY GZ

H.K.

514 80

EU IC

ID

IM IN

10

IQ

13

.

ANTIGUA AFGHANISTAN ALGERIA ALBANIA ANDORRA ANGOLA AMERICAN SAMOA ARGENTINA AUSTRALIA ASHHORE AND CARTIER ISLANDS AUSTRIA ANGUILLA ANTARCTICA BAHRAIN BARBADOS BOTSVANA ACUVASE SELGIUM THE SAMAHAS. BANGLADESH BELIZE BURMA SOLCHON ISLANDS NAVASSA ISLAND SRAZIL SHUTAN BULGARIA SOUVET ISLAND SRUNEI JUBUNOI GERMANY BEBLIN CANADA KANPUCHEA CIAD SRI LANKA CONGO ZAISE CEINA CEILE CATMAN ISLANDS COCOS (XEELING) ISLANDS CAMERCON CAMEROON COMOBOS COLOMBIA NORTSERN MARIANA ISLANDS CORAL SEA ISLANDS CORAL SEA ISLANDS CORAL ARICA CADE VERDE CODE ISLANDS CTPRUS CTCRUSLOVAKIA DENMARK DJIBOUTI BENIN BENIN SENIN Dominica Dominican Republic Ecuador Ecuador TRELIND EQUATORIAL GUINEA EL SALVADOR ETHIOPIA FALKLAND ISLANDS FRENCH GUIANA FINLAND FAROE ISLANDS FRENCH POLIMESIA PRANCE PRENCH SOUTHERN AND ANTARCTIC LANDS RANCONGUILING GAMBIA, THE GISON GIRON DEMOCRATIC REPUBLIC GERMANY, FIDERAL REPUBLIC OF GHANA GIBRALTAR GRENADA GUERNSEY CUADELOUPE GUAM

GREECE GUATEMALA GUINEA CUT ANA GAZA STRIP HAITI HONG KONG HEARD ISLAND AND MCDONALD ISLANDS RONDURAS HUNGLEY ICELUID INDONESIA MAN, ISLE OF BRITISE INDIAN OCEAN TEN ITORY U.S. MISCELLANEOUS PACIFIC INLANDS IRAN ISRAEL ITALY ITORY COAST IRAQ-SAUDI ARABIA MEUTRAL JONE 1210 nundes support JAPAN JERSEY ADIANAL JANA KAL BETAK MALO JOHNSTON ATOLL ATTES A KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF CIRIBATI COREA Republic of CHRISTHAS ISLAND asessfrasfrastersered **EUVALT** LAGS LIBERIA LIECATENSTEIN LISOTRO LUXIDABOURG LIBTA VADAGASCIR MARTINIQUE MACIN MONGOLIA WONTSERRAT VALAWI YALI YORACO YOROCCO MAURITIUS MIDWAY ISLANDS MAURITANIA MALTA CHAN MALDIVES MEXICO MALATSTA NOTANETOUR NETTERLANDS ANTILLES NIUS NORFOLE ISLAND VANUATU STGERTA STATISTIC LINUS NORVAY MEPAL TRUST TERRITORY OF THE PACIFIC ISLANDS NAURU 518 SURINAME NICLEAGUA 33 30 NET LEALAND PARAGUAY PITCALEN ISLANDS ********* 7280 PARACIL ISLANDS PAKISTAN PANAMA PORTUGAL

LISTING OF COUNTRY CODES - Page 2

۰.

. .

. .

ì 1

• • 1:

1

Π

PAPUA NEW GUINEA GUINEA-BISSAG GATAR BEUNION SEUNICS ROMANIA PHILIPPINES PUERTO RICO REANDA SAUDI ARABIA ST. PIEREE AND MIQUELON SAINT CREISTOPREE-NEVIS-ANGUILLA SETCHELLES SOUTH AFRICA SETCHELLES SOUTH AFRICA SENEDAL ST. RELEVA STREA LEORE SAN MARINO SINGAPORE SOMALIA SPALM ST. LUCIA SUDAM STALBARD STRLA STEDEN STALA STITZERLAND UNITED ARAS SMIRATES TRINIDAD and TOBAGO TIAILAND TOBAGA CAICOS ISLANDS TOWNA TORGA TOGO SAO TOME AND PRINCIPS TUBLIA TUBLI TUVALU TAIYAN TANZANIA, UNITED REPUBLIC OF DIANTA TAITAN TANZANIA, UNITED REPUBLIC --OGANDA UNITED EINGDOM UNION OF SOVIET SOCIALIST REPUBLICS UNITED STATES UPPER VOLTA UROGUAF ST. VINCENT and the GRENADINES VENETURIA BRITISH VIRGIN ISLANDS VIETNAM VIRGIN ISLANDS VIETNAM VIRGIN ISLANDS VALLIS AND FUTUNA VALLIS (SANA) TUGGILATIA TEMEN (ADEN) ZAMBIA

TABLE 2

LANGUAGE CODE TABLE - Partial Listing

. . FRE FRENCH GER GERMAN ITA ITALIAN LATIN LAT POL POLISH RUSSIAN rus .

F XIISH

ENG

; .

. -

....

•••

.:

[ī

ا موادی مان در **بورسته منه ک**ومی کار این بود. موادی ماها این مر**بورسته منه** کومی کار این بود. با

.

.

SPA SPANISH

> NOTE: Code consists of first three letters of the name of the language of the article being abstracted.

> > ۰.

Gill Associates, Inc.

Appendix C

•

3

Ten Sample Unit Records

Ι

.....

. • -

Ī.

...

~ -

. .

. .

.

1.

1:

Π

:00000229 ACCESSION NUMBER DISTRIBUTION STATUS :UL :U SECURITY CLASS :US COUNTRY CODE NO. OF FICHE :0 : ENG LANGUAGE CODE DOCUMENT TYPE :J :7 NO. OF PAGES :1966 PUBLICATION YEAR :8 VOLUME NUMBER :4 NO. OF GRAPHICS :0 FICHE LOCATOR :533-539 PAGE RANGE :9 NO. OF REFERENCES AUTHORS : LOOMIS TED A JOHNSON DENNIS D CAS REGISTRY NUMBERS : 96-64-0 67-68-5 76-03-9 50-06-6 55-48-1 51-84-3 : INDEX TERMS AGING SOMAN NEUROMUSCULAR FUNCTION OXIMES DIMETHYL SULFOXIDE PHOSPHONYLATION ACETYLCHOLINESTERASE RATS (SPRAGUE-DAWLEY) PENTOBARBITAL ANTERIOR TIBIAL MUSCLE SCIATIC NERVE ISOTONIC CONTRACTIONS STIMULATION ATROPINE SULFATE NUCLEOPHILIC OXIMES REACTIVATION SOMAN-INHIBITED ACHE TMB-4 TCIA F150

ENZYMES TEMPERATURE DMSO POTENTIATED TWITCH RESPONSE TETANIC RESPONSE BLOCKADE ACETYLCHOLINE TWITCH RESPONSE TETANIC RESPONSE CHOLINESTERASE N-METHYLPYRIDINE 2-ALDOXIME TRICHLOROACETATE AFFILIATION DEPARTMENT OF PHARMACOLOGY, SCHOOL OF MEDICINE, UNIVERSITY OF WASHINGTON, SEATTLE, WASHINGTON 98105 SOURCE TITLE :TOXICOLOGY AND APPLIED PHARMACOLOGY PERFORMING ORGANIZATION : DEPARTMENT OF PHARMACOLOGY, SCHOOL OF MEDICINE, UNIVERSITY OF WASHINGTON, SEATTLE, WASHINGTON 98105 SPONSORING ORGANIZATION : DEPARTMENT OF PHARMACOLOGY, SCHOOL OF MEDICINE, UNIVERSITY OF WASHINGTON, SEATTLE, WASHINGTON 98105 TITLE (DOCUMENT) AGING AND REVERSAL OF SOMAN-INDUCED EFFECTS ON NEUROMUSCULAR FUNCTION WITH OXIMES IN THE PRESENCE OF DIMETHYL SULFOXIDE ABSTRACT/DIGEST THE CURRENT SERIES OF EXPERIMENTS STUDIED THE ROLE OF THE AGING PROCESS IN THE FAILURE OF OXIMES TO INDUCE RECOVERY OF SOMAN-INHIBITED NEUROMUSCULAR FUNCTION, AND TO REACTIVATE THE SOMAN-INDUCED PHOSPHONYLATED ACETYLCHOLINESTERASE. STUDIES WERE CONDUCTED ON 300-500 G SPRAGUE-DAWLEY RATS ANESTHETIZED WITH 30 MG/KG PENTOBARBITAL, I.P. THE ANTERIOR TIBIAL BRANCH OF THE LEFT SCIATIC NERVE WAS ARRANGED FOR STIMULATION AND FOR RECORDING OF ISOTONIC CONTRACTIONS OF THE CORRESPONDING ANTERIOR TIBIAL MUSCLE AS OBTAINED FROM A LINEAR TRANSFORMER. STIMULUS VOLTAGE WAS ALWAYS SUPRAMAXIMAL (0.6 V, 4-MSEC DURATION). EACH ANIMAL WAS PRETREATED WITH 1 MG/KG ATROPINE SULFATE I.V. TWO NUCLEOPHILIC OXIMES WERE USED FOR REACTIVATION OF SOMAN-INHIBITED ACHE: 1,1'-TRIMETHYLENEBIS (4-FORMYLPYRIDINIUM) DIOXIME DICHLORIDE (TMB-4) AND N-METHYLPYKIDINE 2-ALDOXIME TRICHLOROACETATE (TCLA). THE SOMAN PREPARATION HAD A PI50 OF 10.2, AND WHEN ADDED TO THE ENZYME IN THE PRESENCE OF THE BUFFER AND ALLOWED TO STAND AT ROOM TEMPERATURE FOR 1, 5, 10, AND 15 MIN, APPROXIMATELY 50% INHIBITION OF THE ENZYME OCCURRED. HOWEVER, WHEN TCLA WAS ADDED IN FINAL CONCENTRATION OF 1.7 X 1C(EXP-5) M AT 2, 5, OR 10 MIN AFTER INCUBATION OF THE SOMAN-ENZYME MIXTURE AT ROOM TEMPERATURE, APPROXIMATELY 50% OF THE SOMAN-INHIBITED ENZYME WAS REACTIVATED

IF THE TCLA WAS ADDED IMMEDIATELY OR WITHIN 2 MIN AFTER ADDITION OF THE SOMAN INHIBITION. THE DOSE OF SOMAN, WHICH PRODUCED 90% (2.7 X 10 (EXP-8) M), DID NOT REACTIVATE ENZYME. TWELVE ANIMALS EACH RECEIVED 0.09 MG/KG SOMAN, I.V., AND GROUPS OF THREE WERE GIVEN 10 MG/KG TMB-4 PLUS 0.5 ML/KG DMSO I.V., AT EACH OF FOUR DIFFERENT TIME INTERVALS (1.5, 5, 10, or 15 MIN) FOLLOWING SOMAN. WHEN TMB-4-DMSO WAS ADMINISTERED AT 1.5-5 MIN AFTER SOMAN, COMPLETE RECOVERY OF NEUROMUSCULAR FUNCTION OCCURRED. ADMINISTRA-TION 10 MIN AFTER SOMAN RESULTED IN PARTIAL RECOVERY, 15 MIN FOLLOWING SOMAN THE MIXTURE PRODUCED BLOCKADE OF THE POTENTIATED TWITCH RESPONSE, BUT NO RECOVERY OF TETANIC RESPONSE. DMSO ALONE HAD ONLY MINOR NEUROMUSCULAR EFFECTS. CONTROL DOSES OF ACETYL-CHOLINE (ACH), 0.1 UG/KG, I.V., PRODUCED NO EFFECT ON THE TWITCH RESPONSE, WHEN A 0.06-0.09 MG/KG, I.V. DOSE OF SOMAN WAS ADMINISTERED, BLOCKADE OF TETANIC RESPONSE WAS EVIDENT, BUT 10 MG/KG I.V. TMB-4 PLUS 0.5 ML/KG DMSO INDUCED RECOVERY. THE CONTROL DOSE OF ACH WAS WITHOUT EFFECT, INDICATING REACTIVATION OF A CHOLINESTERASE MECHANISM. AFTER 60 MIN, INJECTION OF ACH RESULTED IN A PROLONGED EFFECT MANIFESTED AS IMPAIRMENT OF THE TWITCH. THE REACTIVATION OF ACHE BY TMB-4-DMSO IS TEMPORARY AND MAY INVOLVE ENHANCEMENT OF TRANSFER OF THE OXIME BY DMSO TO THE SITE OF THE SOMAN-INHIBITED ENZYME. :109

BASIS KEY RECORD SECURITY

:0

• •

. .

-

• •

ACCESSION NUMBER :00000343 DISTRIBUTION STATUS :UL SECURITY CLASS :U COUNTRY CODE :US NO. OF FICHE :0 LANGUAGE CODE :ENG DOCUMENT TYPE :R NO. OF PAGES :12 PUBLICATION YEAR :1972 NO. OF GRAPHICS :1 FICHE LOCATOR : 0 PROJECT NUMBER :1W652710AD2502 NO. OF REFERENCES :19 REPORT NUMBERS : AD741015 EASP 1100-6 AUTHORS : THOMAS NORMAN C FLEISHER JOSEPH H HARRIS LARREL W CAS REGISTRY NUMBERS : 96-64-0 306-44-5 55-92-5 51-84-3 7558-80-7 76-03-9 INDEX TERMS PINACOLYL METHYLPHOSPHONATE SOMAN-PHOSPHONYLATED ACETYLCHOLINESTERASE RADIOACTIVITY PHOSPHORUS ORGANOPHOSPHATE INTOXICATION INTOXICATION ACETYLCHOLINESTERASE SOMAN METHYLPHOSPHONATE TISSUE DOGS BRAIN CAUDATE NUCLEUS THALAMUS MEDULLA HIPPOCAMPUS

CEREBRAL CORTEX CEREBELLAR CORTEX REACTIVITY AGING MINA DOZERYTHROCYTE ACHE DEALKYLATION ACETYL-BETA-METHYLCHOLINE DOG BRAIN HOMOGENATES ACETYLCHOLINE SODIUM PHOSPHATE ACETYLCHOLINE IODIDE INHIBITION RADIOPHOSPHORUS BRAIN HOMOGENATES ALIQUOTS TRICHLOROACETIC ACID BOVINE ALBUMIN METHYL 32-P PHOSPHONATE PINACOLYL METHYL 32-P PHOSPHONATE PHOSPHONYLATED AFFILIATION DEPARTMENT OF THE ARMY, EDGEWOOD ARSENAL, BIOMEDICAL LABORATORY, EDGEWOOD ARSENAL, MD 21010 PERFORMING ORGANIZATION DEPARTMENT OF THE ARMY, EDGEWOOD ARSENAL, BIOMEDICAL LABORATORY, EDGEWOOD ARSENAL, MD 21010 SPONSORING ORGANIZATION DEPARTMENT OF THE ARMY, EDGEWOOD ARSENAL, BIOMEDICAL LABORATORY, EDGEWOOD ARSENAL, MD 21010 TITLE (DOCUMENT) UTILIZATION OF [(EXP32)P] SOMAN FOR MEASUREMENT OF ACETYLCHOLINES-TERASE IN BRAIN TISSUES COMMENT :SEE ALSO ACC # 0342 ABSTRACT/DIGEST DTIC VERIFIED FACSIMILE OF: THOMAS, N. C., FLEISHER, J. H., AND HARRIS, L. W., UTILIZATION OF [(EXP32)P] SOMAN FOR MEASUREMENT OF ACETYLCHOLINESTERASE IN BRAIN TISSUES. BIOCHEM BIOPHYS. ACTA, 235:542-547, 1971. DTIC DATE: 1972. BASIS KEY :28 RECORD SECURITY :0

1.



. .

11

1

والمروية والمحادث والمراجع والمحاجم والمعاد المطاري

ACCESSION NUMBER :00000062 DISTRIBUTION STATUS :UL :U SECURITY CLASS :NL COUNTRY CODE NO. OF FICHE :0 LANGUAGE CODE :ENG DOCUMENT TYPE :J :11 NO. OF PAGES :1957 PUBLICATION YEAR VOLUME NUMBER :26 NO. OF GRAPHICS :10 FICHE LOCATOR :0 PAGE RANGE :29-39 NO. OF REFERENCES :20 AUTHORS : COHEN J A WARRINGA M G P J CAS REGISTRY NUMBERS : 77-81-6 107-44-6 96-64-0 55-91-4 7439-96-5 INDEX TERMS : TABUN SARIN SOMAN DFP HOG KIDNEY DFP-ASE ETHYLMETHANEFLUOROPHOSPHONATE PROPYL-1-2-ETHANEFLUOROPHOSPHONATE (2-2-DIMETHYL PROPYL)-1-METHANEFLUOROPHOSPHONATE NERVE GAS ANTICHOLINESTERASE POISONING RATS MANGANESE PROTEINS METAL IONS COFACTORS FLUOROPHOSPHORIC ACIDS CYCLOHEXYL METHANEFLUOROPHOSPHONATE

PROPYL-1-METHANEFLUOROPHOSPHONATE (2-2-DIMETHYLPROPYL) -1-METHANEFLUOROPHOSPHONATE PROPYL-2 ETHANEFLUOROPHOSPHONATE PROPYL-1-2-ISOPRCPANE FLUOROPHOSPHONATE PROPYL-1-2-CYCLOHEXANE FLUOROPHOSPHONATE HYDROLYSIS INHIBITION OF HYDROLYSIS ELECTROPHORETIC PRODUCT CHOLINE ESTERS AFFILIATION MEDICAL BIOLOGICAL LABORATORY OF THE NATIONAL DEFENCE RESEARCH COUNCIL T.N.O., RIJSWIJK, Z.H. (THE NETHERLANDS) SOURCE TITLE :BIOCHIM. BIOPHYS. ACTA PERFORMING ORGANIZATION : MEDICAL BIOLOGICAL LABORATORY OF THE NATIONAL DEFENCE RESEARCH COUNCIL T.N.O., RIJSWIJK, Z.H. (THE NETHERLANDS) SPONSORING ORGANIZATION MEDICAL BIOLOGICAL LABORATORY OF THE NATIONAL DEFENCE RESEARCH COUNCIL T.N.O., RIJSWIJK, Z.H. (THE NETHERLANDS) TITLE (DOCUMENT) PURIFICATION AND PROPERTIES OF DIALKYLFLUOROPHOSPHATASE ABSTRACT/DIGEST INTEREST IN NERVE GASES (TABUN, SARIN AND SOMAN) AND RELATED COMPOUNDS LIKE DIISOPROPYLPHOSPHOROFLUORIDATE (DFP), TOGETHER WIT GROWING THERAPEUTIC, DIAGNOSTIC, AND AGRICULTURAL USES OF SIMILAR JHEMICALS AS INSECTICIDES, HAS FOCUSED ATTENTION ON METABOLISH IN MAN. BASED UPON FRACTIONATION OF HOG KIDNEY EXTRACTS WITH ALCOHOL, A DFP-ASE ENZYME PREPARATION B(SUB1)) WAS FOUND TO BE 100-150 TIMES MORE PURE THAN THE ORIGINAL KIDNEY HOMOGENATE AND 2 5 TIMES MORE PURE THAN FRACTION A. FLUOROPHOS-PHATASE (DFP-ASL) ACTIVITY WAS ASSESSED BY THE WARBURG METHOD: ACTIVATION OF DEP-ASE. MANGANESE CHLORIDE PRODUCED MARKED THITION OF DFP-ASE. P-CHLOROMECURIBENZOIC ACID ACTIVATION. (PCP) IN A CONTRATION OF 1.66 x 10 (EXP-5) PRODUCED 50% INHI-SITION ON INCUBATION AT 37 DEGREES C FOR 15 MIN. INHIBITION WAS REVERSED BY INCUBATING THE ENZYME WITH 10 (EXP-3) M CYSTEINE. SPECIFICITY OF DFP-ASE WAS INVESTIGATED FOR A LARGE NUMBER OF COMPOUNDS: (1) ETHYLMETHANEFLUOROPHOSPHONATE, (2) PROPYL-1-METHANEFLUOROPHOSPHONATE, (3) SARIN, (4) (2-2-DIMETHYLPROPYL)-1-METHANEFLUOROPHOSPHONATE, (5) SOMAN, (6) CYCLOHEXYL METHANE-FLUOROPHOSPHONATE, (7) PROPYL-2-ETHANEFLUOROPHONATE, (8) PROPYL-2-ISOPROPANE FLUOROPHOSPHONATE, AND (10) TABUN. HYDROLYSIS WAS STRONGLY ACTIVATED BY TABUN AND DFP, BUT NOT BY COMPOUNDS 1-9 EXCEPT COMPOUND 2. FOR ALL OTHER COMPOUNDS, MANGANESE CAUSED INHIBITION OF HYDROLYSIS. ACTIVATION WAS OBSERVED IN ALL COMPOUNDS EXCEPT SOMAN COMPOUNDS 6 AND 9 WHEN MANGANESE AND FRACTION G (AN

and the second states and a se

ELECTROPHORETIC PRODUCT WITH DFP-ASE ACTIVITY) WERE ADDED. CHOLINE ESTERS IN HIGH CONCENTRATION CAUSED INHIBITION OF DFP HYDROLYSIS BY DFP-ASE. HOMOGENEITY OF DFP-ASE IN B PREPARATIONS. IN B PREPARATIONS, ONE AND THE SAME ENZYME IS PROBABLY RESPONSIBLE FOR THE HYDROLYSIS OF THE ESTERS OF FLUOROPHOSPHONIC AND FLUORO-PHOSPHORIC ACIDS. IT IS UNCERTAIN WHETHER THE SAME ENZYME IS RESPONSIBLE FOR TABUN HYDROLYSIS. EXPERIMENTAL TREATMENT OF ANTI-CHE POISONING CONDITIONS ONLY ALLOWS CONCLUSIONS PERTAINING TO PROPYLAXIS AND NOT THERAPY. ONLY A PREPARATIONS HAVE BEEN USED. FEMALE RATS (110-160(SUBG)) RECEIVED 1 ML, I.V., DFP-ASE FOLLOWED 1-3 MIN BY LETHAL S.C. DOSE OF 4 MG/KG DFP OR 400-500 UG/KG SARIN. OF 23 TREATED ANIMALS, 18 SURVIVED. ALL 16 UNTREATED CONTROLS DIED. TREATMENT SAVED 16 OF 38 SARIN-POISONED RATS, AND KILLED 17 OUT OF 18 CONTROLS. MANGANESE HAD NO EFFECT ON SURVIVAL. IT WAS CONCLUDED THAT THE ACTIVITY CRUDE HOMOGENATES OF DFP-ASE CANNOT BE PROPERLY ASSESSED BECAUSE OF THE MULTIPLE ENZYMES OF RELATED SPECIFICITY, OTHER PROTEINS, METAL IONS, COFACTORS, AND INHIBITORS. BASIS KEY :66 RECORD SECURITY :0

ACCESSION NUMBER	:00000291				
	:UL				
SECURITY CLASS	:U				
SECURITY CLASS COUNTRY CODE	:NL				
	:0				
	: ENG				
	:J				
NO. OF PAGES PUBLICATION YEAR	:4				
PUBLICATION YEAR					
	:2				
NO. OF GRAPHICS	:2				
FICHE LOCATOR	:0				
FICHE LOCATOR PAGE RANGE NO. OF REFERENCES	:989-992				
	•				
POLAK R L					
MEEKS MARIA M CAS REGISTRY NUMBERS					
51-84-3	•				
51-55-8					
96-64-0					
7782-44-7					
124-38-9					
55-48-1					
7447-40-7					
64-47-1					
INDEX TERMS	•				
BRAIN TISSUE	•				
ANTICHOLINESTERASE					
ACETYLCHOLINE					
ATROPINE					
RAT BRAIN					
CORTICAL SLICES					
SOMAN					
KREBS SOLUTION					
OXYGEN					
CARBON DIOXIDE					
DORSAL LEECH MUSCLE					
INCUBATION					
ATROPINE SULFATE					
POTASSIUM CHLORIDE					
ESERINE SULFATE					
AFFILIATION					
MEDICAL BIOLOGICAL LABORAT					
ORGANIZATION TNO, LANGE KL	EIWEG 139,	RIJSWIJK	(Z.H.),	THE NETHERL	ANDS

I

I

I

ł

I

.....

SOURCE TITLE :BIOCHEMICAL PHARMACOLOGY PERFORMING ORGANIZATION MEDICAL BIOLOGICAL LABORATORY OF THE NATIONAL DEFENSE RESEARCH ORGANIZATION TNO, LANGE KLEIWEG 139, RIJSWIJK (Z.H.), THE NETHERLANDS SPONSORING ORGANIZATION : MEDICAL BIOLOGICAL LABORATORY OF THE NATIONAL DEFENSE RESEARCH ORGANIZATION TNO, LANGE KLEIWEG 139, RIJSWIJK (Z.H.), THE NETHERLANDS TITLE (DOCUMENT) THE INFLUENCE OF ATROPINE ON THE RELEASE AND UPTAKE OF ACETYLCHOLINE BY THE ISOLATED CEREBRAL CORTEX OF THE RAT ABSTRACT/DIGEST BRAIN TISSUE BROUGHT IN CONTACT WITH ANTICHOLINESTERASE AGENTS RELEASES ACETYLCHOLINE (ACH) INTO ITS SURROUNDINGS. THE PRESENT STUDY INVESTIGATED THE INFLUENCE OF ATROPINE ON THE IN VITRO RELEASE AND UPTAKE OF ACH BY RAT BRAIN. RAT CORTICAL SLICES (150 MG, 0.4 MM THICK) WERE PRETREATED WITH 0.005 MM SOMAN. INCUBATED FOR 1 HR AT 37C IN 2.5 ML OF MODIFIED KREBS SOLUTION (TO CORRECT FOR SUBSTANCES OTHER THAN ACH, WHICH MIGHT INFLUENCE SENSITIVITY OF THE ASSAY PREPARATION); THE MEDIUM WAS SATURATED WITH 95% O(SUB2) AND 5% CO(SUB2). (1.) ACH ACTIVITY OF SLICES AND INCUBATING MEDIA WAS ESTIMATED BY BIOASSAY ON THE ESERINIZED DORSAL LEECH MUSCLE. ACH WAS SET FREE INTO THE MEDIA DURING INCUBATION. FIVE TIMES AS MUCH ACH WAS RELEASED WHEN THE MEDIUM CONTAINED 25 MM KCL AS IN A 4.7 MM KCL MEDIUM. THE ACH CONTENT OF THE TISSUE DID NOT CHANGE DURING INCUBATION IN EITHER MEDIUM. ADDITION OF 1 UG/ML ATROPINE SULFATE TO THE 25 MM KCL MEDIUM RESULTED IN A THREEFOLD ENHANCEMENT OF ACH RELEASE PLUS A RISE OF THE ACH CONTENT OF THE TISSUE. ATROPINE SULFATE (0.05 UG/ML) INCREASED THE ACH OUTPUT: 10 UG/ML PRODUCED THE SAME EFFECT AS 1 UG/ML. NO SIGNIFICANT ATROPINE EFFECT WAS OBSERVED IN A MEDIUM CONTAINING 4.7 MM KCL. (2.) UPTAKE OF ADDED ACH WAS STUDIED BY TREATING CORTICAL SLICES WITH SOMAN AND INCUBATING TISSUE IN A MEDIUM CONTAINING 4.7 MM KCL, 25 MM KCL, OR 25 MM KCL PLUS 1 UG/ML ATROPINE. ACH (4 UG/ML) WAS ADDED AT START OF INCUBATION. THERE WAS SIGNIFICANT TISSUE UPTAKE OF ACH AGAINST A CONCENTRATION GRADIENT. ATROPINE DID NOT SIGNIFICANTLY INHIBIT THIS UPTAKE IN A CONCENTRATION AT WHICH IT MOST ENHANCED THE OUTPUT OF ENDOGENOUS ACH. IN THE EXPERIMENTS USING NORMAL KREBS SOLUTION WHERE ENDOGENOUS ACH PRODUCTION WAS SMALL, ACH CONCENTRATION OF THE MEDIA DECREASED. A SMALLER DECREASE OF ACH IN THE MEDIUM WAS OBSERVED WITH THE 25 MM KCL SOLUTION. SMALLEST REDUCTION OF ACH WAS NOTED IN THE 25 MM KCL MEDIUM WITH ATROPINE, WHICH ALSO PRODUCED LARGE AMOUNTS OF ENDOGENOUS ACH. THE ADDED ACH WAS DISTRIBUTED SIMILARLY BETWEEN TISSUE AND MEDIUM IN ALL THREE MEDIA; DIFFERENCES IN RESULTS WERE CAUSED BY CHANGES IN THE CONCENTRATION OF ENDOGENOUS ACH IN TISSUES AND MEDIA PRODUCED BY ADDITION OF KCL AND ATROPINE

TO THE MEDIUM. (3.) THE EFFECT OF ATROPINE SULFATE ON UPTAKE OF ACH WAS STUDIED. KEEPING THE CONCENTRATION OF ADDED ACH CONSTANT DURING INCUBATION OF 75 MG SLICES IN 5 ML OF MEDIUM WITH 25 MM KCL FOR 30 MIN. ATROPINE (10 UG/ML) INHIBITED ACH UPTAKE BY 25% AND 100 UG/ML ATROPINE INHIBITED UPTAKE BY 70%. (4.) EFFECTS OF KCL AND ATROPINE ON ACH OUTPUT WAS INVESTIGATED USING A MEDIUM CONTAINING ESERINE SULFATE (0.4 MM) AS THE CHE INHIBITOR. ACH UPTAKE WAS EXTREMELY SMALL AND ACH CONCENTRATION IN THE TISSUE FELL TO APPROXIMATELY 4 UG/ML IN TESTS WHERE THE MEDIUM CONTAINED ESERINE SULFATE PLUS 25 MM KCL WITH OR WITHOUT ATROPINE. THE AUTHORS CONCLUDED THAT ESERINE SULFATE (0.4 MM) STRONGLY INHIBITS UPTAKE OF ACH, SIMILAR TO RESULTS OBTAINED WITH SOMAN. BASIS KEY :121 RECORD SECURITY

A REAL PROPERTY OF

:0

ź

......

**

•

. .

. .

• •

• •

.

. .

۰.

T

1 ...

Γ

and the second second

÷

ACCESSION NUMBER :00000293 DISTRIBUTION STATUS :UL SECUFITY CLASS :U COUNTRY CODE :CA :0 NO. OF FICHE LANGUAGE CODE : ENG DOCUMENT TYPE :J NO. OF PAGES :13 PUBLICATION YEAR :1972 VOLUME NUMBER :200 NO. OF GRAPHICS :7 :0 FICHE LOCATOR PAGE RANGE :231-244 NO. OF REFERENCES :18 AUTHORS : PRESTON E HEATH C CAS REGISTRY NUMBERS : 51-55-8 107-44-6 55-91-4 96-64-0 INDEX TERMS : RESPIRATORY FAILURE INTOXICATION ORGANOPHOSPHATE CHOLINESTERASE INHIBITORS HYPOXIA CARDIOVASCULAR SYSTEM BLOOD PRESSURE HYPOTENSION BRADYCARDIA PERIPHERAL VASCULAR RESISTANCE CARDIOVASCULAR COLLAPSE ATROPINE SARIN CARDIOVASCULAR HOMEOSTASIS RATS DFP OXIME THERAPY SOMAN RABBIT (WHITE) AUTOPERFUSION VASAL VASOMOTOR TONE VASOMOTOR PATHWAY MYOCARDIAL TOXICITY

• .

Sec. 1 Salar

AFFILIATION DEFENCE RESEARCH ESTABLISHMENT, SUFFIELD, ALBERTA, CANADA, AND THE DEPARTMENT OF PHARMACOLOGY, UNIVERSITY OF ALBERTA, EDMONTON, ALBERTA, CANADA SOURCE TITLE :ARCH. INT. PHARMACODYN. PERFORMING ORGANIZATION : DEFENCE RESEARCH ESTABLISHMENT, SUFFIELD, ALBERTA, CANADA, AND THE DEPARTMENT OF PHARMACOLOGY, UNIVERSITY OF ALBERTA, EDMONTON, ALBERTA, CANADA SPONSORING ORGANIZATION : DEFENCE RESEARCH ESTABLISHMENT, SUFFIELD, ALBERTA, CANADA, AND THE DEPARTMENT OF PHARMACOLOGY, UNIVERSITY OF ALBERTA, EDMONTON, ALBERTA, CANADA TITLE (DOCUMENT) ATROPINE-INSENSITIVE VASODILATATION AND HYPOTENSION IN THE ORGANOPHOSPHATE-POISONED RABBIT ABSTRACT/DIGEST RESPIRATORY FAILURE IS THE PRIMARY CAUSE OF DEATH FROM INTOXICATION WITH THE ORGANOPHOSPHATE CHOLINESTERASE INHIBITORS. APART FROM THE EFFECT OF HYPOXIA, THESE COMPOUNDS DIRECTLY IMPAIR THE CARDIO-VASCULAR SYSTEM, WHICH MAY CONTRIBUTE TO A RAPIDLY FATAL OUTCOME. THE BLOOD PRESSURE RESPONSE IN UNTREATED LETHAL POISONING IS USUALLY HYPOTENSION, THE SEVERITY OF WHICH IS GOVERNED BY INTERACTION OF A DECREASE IN CARDIAC OUTPUT DUE TO BRADYCARDIA AND AN INCREASE IN PERIPHERAL VASCULAR RESISTANCE. LOWERED CARDIAC OUTPUT CAUSES STAGNANT HYPOXIA, WHICH ALSO PROMOTES CARDIOVASCULAR COLLAPSE. ARTIFICIALLY VENTILATED AND ATROPINIZED ANIMALS MAINTAIN A NORMAL BLOOD PRESSURE THOUGH POISONED WITH VERY LARGE DOSES OF SARIN. THIS IMPLIES THAT ATROPINE AND ARTIFICIAL VENTILATION WILL ENSURE CARDIOVASCULAR HOMEOSTASIS DESPITE SEVERE INTOXICATION. IT HAS BEEN SHOWN, HOWEVER, THAT RATS DIE OF CARDIAC FAILURE FOLLOWING A LARGE DOSE OF DIISOPROPYL PHOSPHONOFLUORIDATE (DFP) DESPITE ATROPINE, ARTIFICIAL VENTILATION, AND OXIME THERAPY. IN THE PRESENT STUDIES, LARGE DOSES OF SOMAN, SARIN, OR DFP ADMINISTERED INTRAVENOUSLY CAUSED SEVERE AND RAPID HYPOTENSION IN THE ANESTHETIZED WHITE RABBIT DESPITE BOTH ARTIFICIAL VENTILATION AND ATROPINE TREATMENT SUFFICIENT TO PREVENT BRADYCARDIA. HYPOTENSION RESULTS FROM AN ATROPINE-INSENSITIVE VASODILATATION, DEMONSTRATED IN THE AUTOPERFUSED SOMAN INDUCES DEPRESSION OF BASAL VASOMOTOR TONE: FORELIMB. HOWEVER, THIS IS ANTAGONIZED BY ATROPINE WHILE SYSTEMIC HYPOTENSION REMAINS PROFOUND. IT IS SUGGESTED THAT HYPOTENSION STEMS FROM ORGANOPHOSPHATE EFFECTS WITHIN THE NEURONAL PORTION OF THE VASOMOTOR PATHWAY. THERE IS NO INDICATION THAT SOMAN HAS A MYOCARDIAL TOXIC PROPERTY. :122 BASIS KEY RECORD SECURITY :0

12 3 33

T

I

I

133

;

.

1.

.....

	ITEM 95	
i		
ł	ACCESSION NUMBER	:00000181
	DISTRIBUTION STATUS	:UL
t	SECURITY CLASS	:U
	COUNTRY CODE	:CA
•	NO. OF FICHE	:0
+		: ENG
1	DOCUMENT TYPE	:J
+	NO. OF PAGES	:6
		:1975
	VOLUME NUMBER	: 34
	NO. OF GRAPHICS	:2
	FICHE LOCATOR	:0
		127-132
	NO. OF REFERENCES	:22
	AUTHORS	:
	JOHNSON DENNIS D	
	WILCOX WILLIAM C	
	CAS REGISTRY NUMBERS	:
•	439-14-5	
	96-64-0	
	51-84-3	
	50-06-6	
	55-48-1	
	INDEX TERMS	:
	DIAZEPAM	
•	ANTICHOLINESTERASE	
	SOMAN	·
	ACETYLCHOLINE	
	BRADYCARDIA RABBITS	
	VALIUM	
	RESPIRATION	
	PENTOBARBITAL	
	ATROPINE SULFATE	
1	TACHYCARDIA	
	HEART RATE	
	HERING-BREUER REFLEX	
	RESPIRATORY DEPRESSION	
	BLOOD PRESSURE	
	HYPOTENSION	
	AFFILIATION	
		, COLLEGE OF MEDICINE, UNIVERSITY OF
	SASKATCHEWAN, SASKATOON, O	
	SOURCE TITLE	:EUROPEAN JOURNAL OF PHARMACOLOGY
· ·		
ť•		

٠

.

STUDIES ON THE MECHANISM OF THE PROTECTIVE AND ANTIDOTAL ACTIONS OF DIAZEPAM IN ORGANOPHOSPHATE POISONING ABSTRACT/DIGEST PREVIOUS STUDIES SUGGEST THAT DIAZEPAM PROVIDES ANTIDOTAL ACTIVITY AGAINST ANTICHOLINESTERASE AGENTS SUCH AS SOMAN BY PREVENTING SOME OF THE CENTRAL EFFECTS OF EXCESS ACETYLCHOLINE. TO MEASURE DIAZEPAM'S EFFECT ON SOMAN~INDUCED BRADYCARDIA, SIX UNANESTHETIZED RABBITS WERE ADMINISTERED 10 UG/KG I.V. SALINE-DILUTED SOMAN, SIX WERE GIVEN 1 MG/KG DIAZEPAM (VALIUM), WHILE SIX WERE GIVEN THE ABOVE DOSES OF DIAZEPAM FOLLOWED BY SOMAN. TO MEASURE DIAZEPAM'S EFFECT ON RESPIRATORY DEPRESSION, ARTIFICIALLY VENTILATED RABBITS, ANESTHETIZED WITH 35 MG/KG PENTOBARBITAL AND PRE-TREATED WITH 1.2 MG/KG ATROPINE SULFATE WERE TESTED IN THE SAME WAY: SIX WERE GIVEN DIAZEPAM, SIX SOMAN, SIX SOMAN FOLLOWED BY ATROPINE, AND TEN SOMAN FOLLOWED BY ATROPINE AND DIAZEPAM. UNANESTHETIZED RABBITS GIVEN SOMAN SHOWED SEVERE BRADYCARDIA (83% OF CONTROL) AND THOSE GIVEN DIAZEPAM SHOWED TEMPORARY TACHYCARDIA (REVERSED WITHIN 30 MIN). DIAZEPAM PRETREATMENT PREVENTED ABNORMAL HEART RATES, (103 +/- 8.5% OF CONTROL). IN ANESTHETIZED ANIMALS (RESULTS NOT PRESENTED STATISTICALLY), DIAZEPAM (1 MG/KG) PRODUCED SLIGHT DEPRESSION OF THE RESPIRATORY RATE, SOMAN (10 UG/KG) REDUCED THE DEPTH OF RESPIRA-TION AND/OR INHIBITED THE HERING-BREUER REFLEX DURING EXPIRATION, WITHOUT RECOVERY WITHIN 30 MIN. SIMILAR DOSAGES IN COMBINATION (DIAZEPAM AFTER SOMAN) FAILED TO REVERSE RESPIRATORY DEPRESSION AND PRODUCED FURTHER RESPIRATORY IMPAIRMENTS. PRETREATMENT WITH 1.2 MG/KG ATROPINE BLOCKED SOMAN-INDUCED BRADYCARDIA, AND REDUCED BLOOD PRESSURE MODESTLY. DIAZEPAM FOLLOWING SOMAN REDUCED BLOOD PRESSURE FURTHER, AN EFFECT WHICH ATROPINE APPEARED TO BLOCK. BOTH SOMAN-INDUCED HYPOTENSION AND ITS REVERSAL WITH SUBSEQUENT ATROPINE (1.2 MG/KG) COINCIDED WITH CHANGES IN RESPIRATORY FUNCTION. PRE-TREATMENT WITH ATROPINE ALONE DID NOT PREVENT RESPIRATORY DEPRESSION. THOUGH A SECOND DOSE AFTER SOMAN REVERSED IT, INDICATING A DOSE-RESPONSE RELATIONSHIP. IN SUMMARY, ADMINISTRATION OF DIAZEPAM FOLLOWING SOMAN-INDUCED RESPIRATORY DEPRESSION EXACERBATED THE DEPRESSION AND RENDERED RABBITS LESS SUSCEPTIBLE TO ATROPINE. THE ANTIDOTAL EFFECTS OF DIAZEPAM ARE THUS NOT ASCRIBED TO REVEPSAL OF RESPIRATORY DEPRESSION. IN CONCLUSION, THE PROTECTIVE EFFECTS OF DIAZEPAM ARE ASCRIBED TO BOTH A NON-SPECIFIC ANTI-CONVULSANT EFFECT THAT REDUCES IMPAIRMENT TO RESPIRATORY CENTERS AND TO THE PREVENTION OF BRADYCARDIA. BASIS KEY :95 RECORD SECURITY :0

DEPARTMENT OF PHARMACOLOGY, COLLEGE OF MEDICINE, UNIVERSITY OF

DEPARTMENT OF PHARMACOLOGY, COLLEGE OF MEDICINE, UNIVERSITY OF

:

PERFORMING ORGANIZATION

SPONSORING ORGANIZATION

TITLE (DOCUMENT)

. .

!

SASKATCHEWAN, SASKATOON, CANADA S7N OWO

SASKATCHEWAN, SASKATOON, CANADA S7N OWO

ACCESSION NUMBER :00000059 DISTRIBUTION STATUS :UL SECURITY CLASS :U COUNTRY CODE :NL NO. OF FICHE :0 LANGUAGE CODE :ENG DOCUMENT TYPE :J NO. OF PAGES :19 :1970 PUBLICATION YEAR NO. OF GRAPHICS : 8 FICHE LOCATOR :0 PAGE RANGE :113-131 NO. OF REFERENCES :23 AUTHORS : COHEN E M CHRISTEN P J MOBACH MISS E CAS REGISTRY NUMBERS : 107-44-6 57-71-6 96-64-0 INDEX TERMS : SARIN 32-P SARIN HYDROLYSIS DAM DIACETYL MONOXIME PLASMA RATS (ALBINO) GUINEA PIGE (WHITE) MICE HEART CAROTID ARTERY HUMAN PLASMA PLASMA ALTESTERASE SOMAN AFFILIATION MEDICAL BIOLOGICAL LABORATORY TNO, 139 LANGE KLEIWEG, RIJSWIJK (Z11), THE NETHERLANDS SOURCE TITLE :MEDICINE PERFORMING ORGANIZATION : MEDICAL BIOLOGICAL LABORATORY TNO, 139 LANGE KLEIWEG, RIJSWIJK (211), THE NETHERLANDS SPONSORING ORGANIZATION: MEDICAL BIOLOGICAL LABORATORY TNO, 139 LANGE KLEIWEG, RIJSWIJK (211), THE NETHERLANDS

TITLE (DOCUMENT) : THE INACTIVATION BY OXIMES OF SARIN AND SOMAN IN PLASMA FROM VARIOUS SPECIES I. THE INFLUENCE OF DIACETYLMONOXIME ON THE HYDROLYSIS OF SARIN

ABSTRACT/DIGEST A METHOD IS GIVEN FOR MEASURING HYDROLYSIS OF LOW CONCENTRATIONS OF 32-P SARIN BASED UPON MEASUREMENT OF THE NON-VOLATILE HYDROLYSIS PRODUCT. DEMONSTRATION WITH 32-P SARIN PERMITTED A STUDY OF THE INFLUENCE OF DIACETYL MONOXIME (DAM) ON THE HYDROLYSIS OF: (1) HEPARINIZED PLASMA OBTAINED FROM THE HEART OR CAROTID ARTERIES OF FEMALE ALBINO RATS, WHITE GUINEA PIGS, OR INBRED FEMALE MICE; AND (2) HUMAN PLASMA FROM VOLUNTEERS. SAMPLES WERE INTOXICATED WITH 0.1 MM SARIN AND CENTRIFUGED FOR 20 MIN. IN ALL SAMPLES, HYDROLYSIS WAS AIDED BY SARINASE AND BY DIRECT INTERACTION OF DAM WITH SARIN. IN THE MOUSE AND RATS, DAM GREATLY ENHANCED THE DES-TRUCTION OF SARIN; AT 1 MM DAM, SARIN IN THE RAT WAS COMPLETELY HYDROLYZED IN 2 MIN. RESULTS CONFIRMED EARLIER FINDINGS THAT DAM UNTIL SARIN IS HYDROLYZED. A SJESEQUENT PAPER FROM THIS STUDY DEALS WITH SOMAN. BASIS KEY :24 RECORD SECURITY :0

÷.,

1

۰.

1

Ì

:00000024 ACCESSION NUMBER DISTRIBUTION STATUS :UL :U · SECURITY CLASS :UK COUNTRY CODE :0 NO. OF FICHE :ENG LANGUAGE CODE :J DOCUMENT TYPE :2 NO. OF PAGES :1953 PUBLICATION YEAR :46 VOLUME NUMBER :0 NO. OF GRAPHICS :0 FICHE LOCATOR :801-802 PAGE RANGE :6 NO. OF REFERENCES : AUTHORS BERRY W K CAS REGISTRY NUMBERS : 107-44-6 77-81-6 96-64-0 55-91-4 59-92-7 INDEX TERMS : BIOCHEMICAL MECHANISMS ANTICHOLINESTERASE POISONING CHOLINESTERASE SARIN TOXICITY DOPA 3,4, DIHYDROXYPHENYLALANINE O-DIHYDROXYBENZENE DERIVATIVES TABUN SOMAN DFP DOPA-SARIN REACTION INHIBITION ENZYMES DOPA OXIDATION AFFILIATION . ARMY CHEMICAL DEFENCE ESTABLISHMENT PORTON DOWN, ENGLAND, AND MINISTRY OF SUPPLY, ENGLAND SECTION OF EXPERIMENTAL MEDICINE AND SOURCE TITLE THERAPEUTICS

the second we and the period of the second disease from

PERFORMING ORGANIZATION ARMY CHEMICAL DEFENCE ESTABLISHMENT PORTON DOWN, ENGLAND, AND MINISTRY OF SUPPLY, ENGLAND SPONSORING ORGANIZATION ARMY CHEMICAL DEFENCE ESTABLISHMENT PORTON DOWN, ENGLAND, AND MINISTRY OF SUPPLY, ENGLAND TITLE (DOCUMENT) BIOCHEMICAL MECHANISMS INVOLVED IN POISONING BY ANTICHOLINESTERASES ABSTRACT/DIGEST EXPERIMENTATION WAS DONE SEEKING A CHEMICAL RESEMBLING THE ACTIVE CENTER OF CHOLINESTERASE (CHE), WHICH WOULD BE NONTOXIC AND YET BE ABLE TO COMBINE WITH SARIN FAST ENOUGH TO PROTECT AN ORGANISM AGAINST SARIN'S TOXIC SIDE-EFFECTS. THE CHEMICAL, 3,4, DIHYDROXY-PHENYLALANINE (DOPA), AND OTHER 0-DIHYDROXYBENZENE DERIVATIVES WERE ABLE TO PROTECT TRUE AND PSEUDO-CHES AGAINST SARIN, TABUN, AND SOMAN AND, TO A LESSER EXTENT, DFP. A DIRECT DOPA-SARIN REACTION APPEARED TO BE INVOLVED, BUT TENTATIVE CONCLUSIONS ARE THAT THE ACTIVE CENTER OF CHE WAS NOT PHENOLIC. DOPA DID NOT REVERSE INHIBITION BY SARIN. ITS PROTECTIVE EFFECT DISAPPEARED ON DILUTION TO A DEGREE THAT WAS THERAPEUTICALLY IMPRACTICABLE. A FURTHER CONCLUSION WAS THAT DOPA MIGHT BE THE PRECURSOR OF A MORE ACTIVE SUBSTANCE. STUDY OF THE PRODUCTS OF ENZYMIC AND NON-ENZYMIC OXIDATION OF DOPA FAILED TO SHOW SUCH A SUBSTANCE. BASIS KEY :7 RECORD SECURITY :0

. .

- 5

. .

Ŀ

÷

ACCESSION NUMBER :00000026 DISTRIBUTION STATUS :UL :U SECURITY CLASS :UK COUNTRY CODE :0 NO. OF FICHE LANGUAGE CODE : ENG DOCUMENT TYPE :J NO. OF PAGES :2 :1970 PUBLICATION YEAR :20 VOLUME NUMBER NO. OF GRAPHICS :0 FICHE LOCATOR :0 :1333-1334 PAGE RANGE NO. OF REFERENCES :10 AUTHORS : BERRY W K CAS REGISTRY NUMBERS : 107-49-3 51-15-0 96-64-0 51-84-3 154-97-2 -* 56-97-3 51-55-8 INDEX TERMS : DIAPHRAGM ACETYLCHOLINESTERASE TETRAETHYL PYROPHOSPHATE PRALIDOXIME ... GUINEA PIGS RATE . . RAT DIAPHRAGM GUINEA PIG DIAPHRAGM ÷. TEPP ۰. LD50 SOMAN --HYDROLYSIS ACETYLCHOLINE OXIMES P2S TMB-4 ATROPINE REACTIVATION AFFILIATION : CHEMICAL DEFENCE ESTABLISHMENT, PORTON DOWN, WILTS., ENGLAND

PERFORMING ORGANIZATION : CHEMICAL DEFENCE ESTABLISHMENT, PORTON DOWN, WILTS., ENGLAND SPONSORING ORGANIZATION : CHEMICAL DEFENCE ESTABLISHMENT, PORTON DOWN, WILTS., ENGLAND TITLE (DOCUMENT) SOME SPECIES DIFFERENCES IN THE RATES OF REACTION OF DIAPHRAGM PARTICULATE ACETYLCHOLINESTERASES WITH TETRAETHYL PYROPHOSPHATE AND PRALIDOXIME ABSTRACT/DIGEST THE DEMONSTRATED EXISTENCE OF TWO FORMS OF ACHE IN THE GUINEA PIG AND RAT DIAPHRAGM -- SOLUBLE AND PARTICULATE FRACTIONS -- HAS BEEN PROPOSED TO EXPLAIN THE FAILURE OF TETRAETHYL PYROPHOSPHATE (TEPP) PRETREATMENT TO RAISE THE LD50 OF SOMAN FOR RATS BY THE SAME DEGREE APPLICABLE TO OTHER SPECIES. THE PRESENT STUDY EXPLORED THE KINETIC PROPERTIES OF GUINEA PIG AND RAT PARTICULATE ACHE TO EXPLAIN THIS PHENOMENON. THE VELOCITY OF HYDROLYSIS OF 5.5 MM ACETYLCHOLINE (ACH) WAS MEASURED FOLLOWED BY ADDITION OF 1 MM RESULTS SHOWED THAT TEPP INHIBITION WAS PSEUDO-REVERSIBLE, TEPP. BEING STABLE PRIOR TO ADDITION OF OXIME. TEPP INHIBITION OF GUINEA PIG DIAPHRAGMS SHOWED 15-20% INHIBITION WITHIN 40-50 MIN, WHILE

SUBSEQUENT ADDITION OF 2-HYDROXYIMINOMETHYL-N-METHYL PYRIDINIUM METHANESULPHONATE (P2S) EQUIVALENT TO THE DIAPHRAGMATIC PORTION 30-60 MIN AFTER 30 MG/KG I.M. PRODUCED REACTIVATION TO 20-30% OF AN EQUIVALENT DOSE OF TMB-4 (1,3-DI (4-NORMAL AFTER 45-50 MIN. HYDROXYIMINO METHYLPYRIDINIUM) PROPANE DIHALIDE) PRODUCED REACTIVATION THE SAME CONCENTRATION OF TEPP INHIBITED RAT TOO RAPID TO PLOT. PREPARATIONS TOO RAPIDLY TO DEVELOP RATE CONSTANTS, REACHING THE LEVELS SEEN IN GUINEA PIGS. SUBSEQUENT P2S CAUSED RAPID REACTIVATION TO 25% OF NORMAL. THE AUTHOR CONCLUDES THAT THE MAJOR FACTOR IN TEPP PROTECTION IS THE SPEED OF INHIBITION AND REACTIVATION. İF GIVEN TO GUINEA PIGS 1 MIN BEFORE SOMAN, PROTECTION WAS EQUIVALENT TO THAT OF ATROPINE AND P2S ALONE, WHILE MAXIMAL PROTECTION RESULTED FROM PRETREATMENT AT 0.5-5 HR PRIOR TO SOMAN. P2S IS EFFECTIVE IN THE GUINEA PIG BECAUSE REACTIVATION LAGS BEHIND SOMAN CLEARANCE FROM THE DIAPHRAGM, WHEREAS RAPID REACTIVATION OCCURS IN THE RAT IN THE PRESENCE OF FREE SOMAN. TMB-4 IS INEFFECTIVE IN THE GUINEA PIG BECAUSE OF THE SAME PHENOMENON OF TOO-RAPID REACTIVATION. BASIS KEY :8 RECORD SECURITY :0

SOURCE TITLE :BIOCHEMICAL PHARMACOLOGY PERFORMING ORGANIZATION ·

ACCESSION NUMBER :00000031 DISTRIBUTION STATUS :UL SECURITY CLASS :U COUNTRY CODE :UK NO. OF FICHE :0 LANGUAGE CODE :ENG DOCUMENT TYPE :J NO. OF PAGES : 8 PUBLICATION YEAR :1966 VOLUME NUMBER :15 NO. OF GRAPHICS :7 FICHE LOCATOR :0 PAGE RANGE :1259-1266 NO. OF REFERENCES :11 AUTHORS : BERRY W K DAVIES D R RUTLAND J P CAS REGISTRY NUMBERS : 96-64-0 51-55-8 107-44-6 INDEX TERMS SOMAN SARIN 3-METHYLBUTYL-2-METHYLPHOSPHONOFLUORIDATE MBPF DIAPHRAGM ACETYLCHOLINESTERASE RATS TUB-4 ATROPINE OXIMES ORGANOPHOSPHATES AFFILIATION ARMY DEPT., CHEMICAL DEFENCE EXPERIMENTAL ESTABLISHMENT, PORTON DOWN, SALISBURY, WILTS. SOURCE TITLE :BIOCHEMICAL PHARMACOLOGY PERFORMING ORGANIZATION : ARMY DEPT., CHEMICAL DEFENCE EXPERIMENTAL ESTABLISHMENT, PORTON DOWN, SALISBURY, WILTS. SPONSORING ORGANIZATION : ARMY DEPT., CHEMICAL DEFENCE EXPERIMENTAL ESTABLISHMENT, PORTON DOWN, SALISBURY, WILTS. TITLE (DOCUMENT) PROBLEMS IN THE TREATMENT WITH OXIMES AND ATROPINE OF RATS POISONED BY ORGANOPHOSPHATES

1.4

ا المحمد ا

. .

ł

7 -

T

E

ABSTRACT/DIGEST

SINCE SOMAN-INACTIVATED ACETYLCHOLINESTERASE (ACHE) CANNOT BE REACTIVATED UNDER PHYSIOLOGICAL CONDITIONS, AN ATTEMPT HAS BEEN MADE TO ASSESS THE SIGNIFICANCE OF AGINC IN VIVO USING THE SOMAN HOMOLOGUE 3-METHYLBUTYL-2-METHYLPHOSPHONOFLUORIDATE (MBPF). SOMAN ITSELF WAS NOT PART OF THE EXPERIMENT, BUT PREVIOUS STUDIES USING SOMAN WERE CITED. SARIN WAS USED FOR COMPARISON WITH MBPF. THIS EXPERIMENT ATTEMPTS TO REACTIVATE DIAPHRAGM ACHE OF THE RAT IN VITRO WITH IMB-4 AND ATROPINE. BASIS KEY :9

فاستعدرت رغو

BASIS .	KEI	:9
RECORD	SECURITY	:0

:

i

-

i

T

Appendix D

_ _ _

Print-Out of Sample Thesaurus

۰.

::

- .

Ī

I

Ŧ


and a second
· · · · ·

a de acte annuel ande s'ara a

THESAURUS

Edited Edition Prepared by: Dr. Hilda Feinberg Dr. Theodore C. Hines

October 21, 1981



1

Γ

Π

-

The second s

Introductory Notes

A desirable objective in an information system is the consistent representation of subject matter in both indexing and searching operations. To this end a controlled standardized vocabulary is frequently used so that both indexing and searching can be conducted using a common language.

The thesaurus serves as an authority list for use in both information indexing and retrieval. It represents an organized, comprehensive, and structured vocabulary listing the terms that have been accepted and approved as a standard by participating members of a specialized user group, in a defined area of information. It specifies those terms that are allowed as authorized "descriptors". The thesaurus indetifies the scope of each term so that all terms are clear and discrete. Ideally, the terms in the thesaurus are sufficiently comprehensive for the identification and communication of information in the defined area covered by the information system.

One of the more important functions of the thesaurus is to display the relationships among terms in the vocabulary, thus aiding the indexer and searcher to select the most appropriate terms when indexing documents, or formulating search requests.

The thesaurus shows synonymous, hierarchical and other relationships. Such a controlled vocabulary promotes maximum consistency in the description of concepts. It serves further as a store of intellectual decisions that have been made as a result of previous indexing and searching operations.

The present thesaurus was designed for post-coordinate indexing. In such a system many terms are combined at the search stage. It was prepared to serve as a base for an open-ended microthesaurus to be used for a specialized data base, and was derived from the following sources:

- (1) Actual documents in the data base
- (2) MeSH (Medical Subject Headings, National Library of Medicine)
- (3) Chemical Abstracts Index Guide (American Chemical Society)
- (4) Merck Index

• 1

(5) Various biomedical and scientific dictionaries and encyclopedias

As new documents are added to the data base, the thesaurus will be expanded accordingly.

Cross references employed in the thesaurus are: USE; USED FOR; RELATED TERM; BROADER TERM; and NARROWER TERM. Scope notes are included where necessary.

(1) USE

The <u>USE</u> reference is intended to lead thesaurus users from a term that is not an authorized term to one that is authorized for indexing and searching.

The USE reference leads to the preferred term.

(2) **JSED FOR**

The <u>USED FOR</u> (UF) reference is the reciprocal of the <u>USE</u> reference, and accompanies the term to which the <u>USE</u> reference refers. It is the reverse of a <u>USE</u> reference, and indicates the access points in the thesaurus referring to the term to be used.

(3) BROADER TERM

The <u>BROADER TERM (BT)</u> reference is employed to refer from a term representing a member of a class of concepts to the term naming that class, for example:

Mammals BT Vertebrates

For each BROADER TERM reference there must also be provided a corresponding NARROWER TERM. The broader term may be one which is higher in a hierarchical relationship than the one under which it appears.

(4) NARROWER TERM

The <u>NARROWER TERM (NT)</u> reference is the reciprocal of the <u>BROADER</u> <u>TERM (BT)</u>. The NT is employed to identify the term as a member of the class represented by the entry, for example:

Vertebrates NT Mammals

For each NARROWER TERM reference there must be provided a corresponding <u>BROADER TERM</u> reference. Ther narrower term, which is the opposite of the broader term, may be used to indicate terms lower in a hierarchical relationship than the one under which it appears.

The whole-part relationship may in some cases be used with the NT/BT designation.

(5) RELATED TERM

. .

1.

-

I

いたのであるというないの

The <u>RELATED TERM (RT)</u> reference is employed as a guide from a given term to other terms that are closely related in ways other than the genus-species (BT/NT) relationship. In general, any two terms bear the cross-reference <u>RT</u> to each other if it is believed that the user, when examining one of them, might want to be remined of the existence of the other. The <u>RT</u> advises the indexer or searcher to consider also the terms designated as related.

(6) SCOPE NOTES

The scope note which accompanies the term, but is not a part of if, is used to designate the scope of the term. It may be used to exclude a possible meaning from the term, and indicate the acceptable term to use for that meaning, or explicitly to include an uncommon meaning under a term. It is used to indicate any intended restrictions in the use of the term. In case of possible misunderstanding, it is used to define a term.

(7) PARENTHETICAL QUALIFIERS

Used sparingly, the parenthetical qualifier may be appended to a term to distinguish among homographs, for example.

Mercury (metal) Mercury (planet)

The parenthetical qualifier is considered as a part of the term, in contrast to the definition given in a scope note.

Thesaurus Displays

A thesaurus may be complete with only an alphabetic display of terms with cross references. In the present thesaurus it is recommended that a numberical and alphabetical display indicating Chemical Abstracts registry numbers be included. At a later period it may be decided that other displays would be useful, for example, a tree-structure display, and a permuted display of terms in which each word of multi-word terms may be accessed alphabetically.

AATP U Parathion Abate BT Insecticides, organothiophosphate Abdomen Abnormalities NT Deformities Absorption, skin U Skin absorption Acetic acid phenyl ester U Phenyl acetate 67-64-1 Acetone Acetonitrile 75-05-8 UF Cyanomethane UF Methyl cyanide 3-Acetoxyindole U Indoxyl acetate 7-Acetoxy-l-methylquinolinium iodide U 7-Ać-Q 8-Acetoxy-l-methylquinolinium iodide U 8-Ac-Q 2-A stoxynaphthalene U Beta-Naphthyl acetate Acetvlation Acetylcarnitine 14992-62-2 UF Carnitine Acetyl Ester Acetylcarnitine chloride U Acetylcarnitine hydrochloride Acetylcarnitine hydrochloride 33661-41-5 4326-58-3 5080-50-2 UF Acetylcarnitine chloride Acetvlcholine 51-84-3 UF Ethanaminium, 2-(acetyloxy)-N, N, N-trimethyl-Acetylcholine bromide 66-23-9 Acetylcholine chloride 60-31-1 Acetylcholine hydrolase Acetylcholine iodide Acetylcholine receptor

۰.

ì

Γ

وي. و در د مونون د مينور توني Acetylcholine release Acetylcholinesterase U AChE Acetylcholinesterase inhibition Acetylcholinesterase inhibitors Acetylcholine uptake Acetylcholine chloride 60-31-1 Acetylcholine perchlorate Acetyl-beta-methylcholine U Methacholine Acetyl-beta-methylcnoline bromide U Methacholine bromide Acetyl-beta-methylcholine chloride U Methacholine chloride O-Acetyl-beta-naphthol U Beta-Naphthyl acetate Acetyl phenol U Phenyl acetate 4468-05-7 Acetylthiocholine BT Choline Acetylthiocholine iodide Acetyltransferase, choline 9012-78-6 UF Choline acetylase UF Choline acetyltransferase Acetyltransferases Acetyltyrosine ethyl ester U N-Acetyl-L-tyrosine ethyl ester Acetyl-L-tyrosine ethyl ester U N-Acetyl-L-tyrosine ethyl ester 840-97-1 N-Acetyl-L-tyrosine ethyl ester UF Acetyltyrosine ethyl ester UF Acetyl-L-tyrosine ethyl ester UF Acetyl-Lotyrosyl ethyl ester UF ATEE UF Ethyl N-acetyl-L-tyrosinate UF Ethyl acetyltyrosinate

. .

j•

I

1. Transie

۰.

Acetyl-L-tyrosyl ethyl ester U Acetyl-L-tyrosine ethyl ester AChE **BT** Cholinesterases UF Acetylcholinesterase Acid-base equilibrium NT Buffers Acidity RT pH Acids RT Bases Acocantherin U Ouabain 7-Ac-Q UF 7-Acetoxy-1-methylquinolinium iodide 8-Ac-Q UF 8-Acetoxy-1-methylquinolinium iodide 9-Acridinamine, 1,2,3,4-tetrahydro-U Tacrine Actinomycin D 50-76-0 UF Cosmegen UF Dactinomycin UF Meractinomycin Acyl groups U Radicals, acyl Adaptation, biological 58-61-7 Adenosine BT Nucleosides 60-92-4 Adenosine 3'5'-cyclic monophosphate UF cAMP UF cyclic AMP Adenosine, N-(1-oxobuiy1)-, cyclic 3', 5'-(hydrogen phosphate) 2'-butanoate U Dibutyryl cyclic AMP Adenosine 5'-phosphorimidazolide 20816-58-4 Adenosine triphosphatase BT Phosphatases UF ATPase Adenosine triphosphate 56-65-5 UF ATP 9012-42-4 Adenylate cyclase UF Adenyl cyclase UF Adenylyl cyclase UF Cyclase, adenylate Adenyl cyclase U Adenylate cyclase

1.





Adenyl cyclase U Adenylate cyclase Adephenine hydrochloride U Trasentine hydrochloride 64-95-9 Adiphenine UF Benzeneacetic acid, alpha-phenyl-, 2(diethylamino)ethyl ester Adrenal Cortex BT Adrenal glands Adrenal glands BT Endocrine glands NT Adrenal Cortex NT Adrenal Medulla NT Interrenal gland Adrenaline U Epinephrine Adrenal Medulla BT Adrenal glands Aging Aging rate Air sacs RT Lung Albumins Alcohol, ethyl U Ethanol Alcohol. methyl U Methanol Alcohols Aldicarb 116-06-3 BT Insecticides, carbamate Aliesterase U Esterase, carboxyl Alitinal U Amobarbital sodium Alkaloids Alkoxy U Radicals, alkoxy Alkylation Alkyl radicals U Radicals, alkyl Allergens **RT** Hypersensitivity Allergy **RT** Hypersensitivity Allosteric regulation AM-1 71006-78-5 UF O-Ethyl, S-diethylaminoethyl ethylphosphonothiolate UF 1H-Imidazole-1-ethanol, alpha-(methoxymethyl)-2-methyl-4-nitro-

5 Ambenonium chloride 115-79-7 BT Cholinesterase inhibitors UF Ambestigminum Ambestigminum U Ambenonium chloride Amechel U Methacholine bromide Amines RT Amino compounds gamma-Aminobutyric acid U GABA Amino compounds **RT** Amines RT Nitrogen beta-Aminoethylglyoxaline U Fistamine Aminoethylphosphonic acid BT Organophosphorus compounds 2-Amino-3-hydroxypropionic acid U Serine alpha-Aminoisocaproic acid U Leucine 2-Amino-4-methylvaleric acid U Leucine Aminooxyacetic acid hemihydrochloride 2921-14-4 Aminophylline 317-34-0 4-Amino-l-beta-D-ribofuranosyl-2-(1H)-pyrimidinone U Cytidine 9-Amino-1, 2, 3, 4-tetrahydroacridine Tacrine U . . Aminotransferase, aspartate U Glutamic oxalacetic transaminase . . 78-53-5 3734-97-2 Amiton BT Cholinesterase inhibitors BT Insecticides ۰. UF O, O-Diethyl S-2-diethylaminoethyl phosphorothioate UF DSDP UF Inferno UF Metramac UF Phosphorothioic acid, esters, S-2[(diethylamino)ethyl] O, O-diethyl este UF Tetrain Ammonium fluoride 12125-01-8 Amobarbital sodium 35942-73-5 64-43-7 UF Alitinal UF Amylobarbitone sodium Ī UF Amytal sodium UF Sodium amobarbital Ţ • .

ŝ

Amobarbital sodium

Amobarbital sodium (cont'd) UF Sodjum amytal Amygdala U Amygdaloid body Amygdaloid body UF Amygdala Amylacetic ester U Isoamyl acetate Amylobarbitone sodium U Amobarbital sodium Amytal sodium U Amobarbital sodium Anaerobiosis BT Metabolism Analgesia RT Pain Anaphylaxis RT Hypersensitivity Anesthesia Anesthesia adjuvants Anesthesia, conduction UF Anesthesia regional Anesthesia, general Anesthesia, inhalation Anesthesia, intravenous Anesthesia, local Anesthesia, regional U Anesthesia, conduction Anesthesia, spinal Anesthetics Anesthetics, local Animals NT Laboratory animals Animals, laboratory U Laboratory animals Animal testing RT Laboratory animals Anions **Anoxia** UF Hypoxia UF Oxygen deficiency Antagonism Antagonists Anthracenecarboxylic acid UF Anthroic acid Anthroic acid U Anthracenecarboxylic acid Anti-arrhythmia agents UF Antifibrillatory agents UF Cardiac depressants UF Myocardial depressants Antibody diversity

. .

• -

17

- --

Ē

متعصيص فأخذونهم

. . . **.** .

وتشغله

Antibody diversity

Antibody diversity (cont'd) BT Immunity Antibody formation BT Immunity Antibody specificity BT Immunity Anticholinergic agents **U** Parasympatholytics Anticholinesterase activity U Cholinesterase inhibitors Anticholinesterase agents U Cholinesterase inhibitors Anticonvulsants Antidotes RT Poisoning Antifibrillatory agents U Anti-arrhythmia agents Antigen-antibody reactions BT Immunity Antimuscarinic agents U Parasympatholytics Antirex U Edrophonium chloride Aonea RT Respiration Apocrine glands BT Sweat glands Arm NT Forearm 546-71-4 Armin BT Organophosphorus compounds UF Armine UF Ethoxy-4-nitrophenyloxy-ethylphosphynoxide UF Ethyl p-nitrophenyl ethylphosphonate UF Phosphonic acid, ethyl-, ethyl 4-nitrophenyl ester Armine U Armin 3098-65-5 Arpenal UF Benzeneacetic acid, alpha-phenyl, 3 (diethylamino)propyl ester, hydrochloride UF N-(3-Diethylaminopropyl)-2-2 diphenylacetamide UF Diophenylacetic acid diethylaminopropylamide UF 1-Propanol, 3-(diethylamino)-, diphenylacetate, hydrochloride Arterenol U Norepinephrine Arterial blood pressure U Blood pressure Arteries Where indicated use names of specific arteries BT Blood vessels

. mar with a series .

铌

A STATE

د.

٩

Artificial respiration U Respiration, artificial Artificial ventilation U Respiration, artificial Aspiration BT Respiration ATEE U N-Acetyl-L-tyrosine ethyl ester Atmosphere ATP U Adenosine triphosphate ATPase U Adenosine triphosphatase Atrioventricular block U Heart block Atrioventricular node 51-55-8 Atropine BT Parasympathomimetics UF Hyoscyamine Atropine methyl bromide U Methylatropine bromide Atropine sulfate 55-48-1 Autonimic fibers ET Neurons Autonomic nervous system BT Nervous system Autoradiography UF Radioautography Axons BT Nerve fibers BT Neurons Axoplasm Azinphosmethyl 86-50-0 BT Insecticides, organothiophosphate Azinphos-methyl U Guthion 8-Azoniabicycle [3.2.1] octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8,8dimethyl-, endo-, nitrate U Methylatropine nitrate 8-Azoniabicyclo [3.2.1] octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8,8dimeth/l-, bromide , endo-U Methylatropine bromide B4FPBOC12 UF 1, 3-bis(4-formylpyridinium-propane)bis-oxime dichloride Back 57-44-3 Barbital BT Barbiturates UF Barbitone UF 2, 4, 6 (1H, 3H, 5H)-pyrimidinetrione, 5, 5-diethyl-UF Veronal

. .

: .

....

nur allehend, alle

Barbital phosphates Barbitone U Barbital Barbiturates BT Hypnotics and Sedatives NT Barbital Bases RT Acids Beak (chicken) 302-40-9 Benactyzine BT Benzilates BT Parasympatholytics UF Benzeneacetic acid, alpha-hydroxy-alpha-phenyl-, esters, 2-(diethylamino ethyl ether UF 2-Diethylaminoethylbenzylate hydrochloride Bensylyt U Dibenzyline Benzalin U Nitrazepam Benzenaminium. 3-[(diethoxy-phosphinyl)-oxy]-N. N. N-trimethyl-, methyl sulfate U Ro-3-0340 Benzenaminium, 3-[[(dimethylamino) carbonyl]oxy]-N, N, N-trimethyl-U Neostigmine Benzenaminium, N-ethyl-3-hydroxy-N, N-dimethyl-, chloride U Tensilon Benzeneacetic acid, alpha-hydroxy- alpha-phenyl-, esters, l-azabicyclo [2.2.2] oct-3-yl ester Ro-2-3308 U Benzeneacetic acid, alpha-hydroxy-alpha-phenyl-, esters, 2-(diethylamino) ethyl ether U Benactyzine Benzeneacetic acid, alpha-hydroxy-alpha-phenyl esters, 1-methyl-3-piperidinyl ester U JB-336 Benzeneacetic acid, alpha-hydroxy-alpha-phenyl-, esters, 1-methyl-4piperidinyl ester, hydrochloride JB-336/4 U Benzeneacetic acid, alpha-hydroxy-alpha-phenyl-, esters, 1-methyl-3-piperidinyl ester, hydrochloride JB 336/3 U

وربعا تنقضه أرارات

9

1.3

```
Benzeneacetic acid, alpha-phenyl-, 2-(diethylamino)ethyl ester
    U Adiphenine
Benzeneacetic acid, alpha-phenyl-, 2-(diethylamino) ethyl ester
       Trasentine
    U
Benzeneacetic acid, alpha-phenyl, 3(diethylamino)propyl ester, hydrochloride
    U Arpenal
Benzenaminium, N-ethyl-3-hydroxy-N, N-dimethyl-
    U Edrophonium
Benzenemethanamine, N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-
    J Dibenzyline
Benzene, methyl-
    U Toluene
Benzenesulfonyl fluoride
Benzilates
    NT Benactyzine
Benzin
         8030-03-06
    NT Naphtha
    NT Petroleum ether
Benzodiazepines
2H-1, 4-Benzodiazepin-2-one, 7-chloro-1, 3-dihydro-1-methyl-5-phenyl-
    U Diazepam
2H-1, 4-Benzodiazepin-2-one, 7-chloro-1, 3-dihydro-1-methyl-5-phenyl-
    U Valium
2H-1, 4-Benzodiazepin-2-one, 1, 3-dihydro-7-nitro-5-phenyl-
    U Nitrazepam
Benzoic acid, 4-amino, 2-(diethylamino) ethyl ester
    U Procaine
Benzoic acid, 3-chloro-2,5,6-trimethyl-
    UF U-23223
Benzoic acid, esters
Benzoic acid, 4-(2-methylpropoxy)-3-(diethylamino)l, 2-dimethylpropyl ester
                    hydrochloride
    U Gangleron
Benzovlcholine
                 2208-04-0 2964-09-2
    BT Choline
```

1

]|

Benzoylcholine

(cont'd) Benzoylcholine UF Choline benzoate UF Choline, benzoyl UF Ethanaminium , 2-(benzoyloxy)-N,N,N-trimethyl-Benzoylcholinesterase U Cholinesterase Benzylyt U Dibenzyline Bicyclo [2.2.1]heptan-2-amine, N,2,3,3-tetramethyl-U Mecamylamine Binding, competitive UF Competitive binding Binding sites Bladder BT Urinary tract Blockage Blood Blood brain barrier RT Cerebrospinal fluid Blood cell count BT Cell count Blood cells BT Cells NT Blood platelets NT Erythrocytas NT Hemocytes NT Leukocytes Blood circulation RT Ischemia **UF** Circulation Elood coagulation Blood flow velocity Blood glucose RT Hyperglycemia Blood levels Blood plasma U Plasma Blood platelets BT Blood cells Blood pressure RT Pressure UF Arterial blood pressure Blood pressure determination Blood pressure, high U Hypertension Blood pressure, low U Hypotension Blood pressure, venous U Venous pressure

11

8.5

-

I

Blood transfusion UF Transfusion Blood vessels NT Arteries NT Veins Body temperature RT Fever RT Temperature RT Thermography RT Thermometers Body temperature changes Body temperature regulation UF Heat loss UF Heat production UF Thermoregulation Body weight RT Weight gain RT Weight loss Bone and Bones Names of specific bones are used where indicated Bone marrow UF Marrow Bone marrow cells BT Cells Borates Botulin U Botulinum toxins Botulinum toxins RT Botulism UF Botulin Botulism RT Botulinum toxins Bovine serum albumin U Serum albumin, bovine Brachial plexus Bradycardia Brain UF Cerebrum Brain stem Breast Breathing NT Inhalation Bromine cyanide U Cyanogen bromide Bromophos BT Insecticides, organothiophosphate Bronchi BT Lung Bronchial arteries Bronchial spasm UF Bronchospasm



Bronchodilation Bronchodilator agents Buffers BT Acid-base equilibrium Bursine U Choline Butanedioic acid [(dimethoxyphosphinothioyl) thio]-, diethyl ester U Malathion 2, 3-Butanedione, monooxime 57-71-6 UF DAM UF Diacetyl monoxime Butanoic acid, 4-amino U GABA Butanoic acid, anhydrides, anhydride U Butyric anhydride 2-Butanol, 3, 3-dimethyl-U Pinacolyl alcohol 2-Butenoic acid, 3-[(dimethoxy-phosphinyl)oxy]-methyl ester U Phosdrin Buttocks Butyl dihydrogen phosphate 1623-15-0 UF Monobutylphosphoric acid Butyl ether 142-96-1 Butyric anhydride 106-31-0 UF Butanoic acid, anhydrides, anhydride U Butyrylcholine iodide Butyrocholine iodide 3922-86-9 Butyrylcholine Butrylcholine bromide 18956-84-8 Butyrylcholine chloride 2963-78-2 Butyrylcholine iodide 2494-56-6 UF Butyrocholine iodide Butyrylcholinesterase U Cholinesterase Butyrylthiocholine BT Choline Butyrylthiocholine iodide 1866-16-6 UF (2-Merceptoethyl)trimethylammonium iodide butyrate Caffeine 58-08-2 Calcium 7440-70-2 Callithricidae UF Marmosets cAMP U Adenosine 3'5'-cyclic monophosphate Cannula Cannulation **U** Catheterization Capillaries 77-22-5 Caramiphen UF Cyclopentanecarboxylic acid, 1-phenyl-2(diethylamino) ethyl ester

- -

1

Ţ

Ī

11

うい いきからかか ぬ

Caramiphen 77-22-5

1

11

のため

Caramiphen 77-22-5 (cont'd) UF Parpanil UF Pentaphen Caramiphene hydrochloride U Caramiphen hydrochloride Caramiphen hydrochloride 125-85-9 BT Parasympatholotics UF 2-Diethylaminoethyl-L-phenyl cyclopentane carboxylate hydrochloride UF Caramiphene hydrochloride UF Caramiphenium chloride UF G 2747 UF Parpanit UF Pentaphene hydrochloride Caramiphenium chloride U Caramiphen hydrochloride Carbachol 51-83-2 BT Parasympatholytics UF Carbacholine chloride UF Carbaminoylcholine chloride UF Carbamylcholine UF Choline carbamate chloride Carbacholine chloride U Carbachol Carbamates Carbamic acid, esters Carbamic acid, esters, ethyl ester 51-79-6 UF Ethyl carbamate UF Urethan UF Urethane Carbamide U Urea Carbaminocholine U Carbamoylcholine Carbaminoylcholine U Carbamoylcholine Carbaminoylcholine chloride U Carbachol Carbamoylcholine 462-58-8 UF Carbaminocholine UF Carbaminoylcholine Carbamylcholine U Carbachol Carbary1 U N-Methyl carbamate Carbohydrate metabolism Carbon 7440-44-0 Carbon dioxide 124-38-9 Carbonic acid, monosodium salt

Carbonic acid, monosodium salt (cont'd) U Sodium bicarbonate Carbonic dichloride U Phosgene 56-23-5 Carbon tetrach! oride poisoning Carbonyl chloride U Phosgene Carbonyl compounds Carbonyldiamide U Urea Carboxylic acids, esters 3-Carboxypyridine N-oxide U Oxiniacic acid Cardiac arrest U Heart arrest Cardiac depressants U Anti-arrhythmia agents Cardiac output Cardiovascular agents Cardiovascular diseases Cardiovascular homeostasis Cardiovascular system Cardiovascular system physiology 541-15-1 Carnitine Carnitine Acetyl Ester U Acetylcarnitine Carotid arteries Carotid body Catalysis Catheterization UF Cannulation Cathode ray oscilloscope U Oscilloscope Cations Cats BT Laboratory animals BT Mammals Caudate nucleus CDP-Choline U Cytidine 5'-diphosphate choline CEES U 2-Chloroethyl ethyl sulfide Cell count BT Cells NT Blood cell count NT Cell wall

Cell division Cell membrane

15

ł

1 :

. .

. .

Ţ.,

. .

• • •

Cell membrane

T

Cell membrane (cont'd) RT Membrane potentials RT Membranes UF Plasma membrane Cell membrane permeability UF Permeability, cell membrane Cell nucleus BT Cells Cells Names of specific cells are used where indicated. NT Blood cells NT Bone marrow cells NT Cell count NT Cell nucleus NT Cytoplasm NT Epithelial cells Cells, cultured Cell wall BT Cell count Central nervous system BT Nervous system Centrum medianum Cerebellar cortex Cerebellum Cerebra¹ blood flow Cerebral cortex Cerebral hemorrhage UF Hemorrhage, cerebral Cerebrospinal fluid RT Blood brain barrier Cerebrum U Brain Cevadine 62-59-0 UF Cevane-3, 4, 12, 14, 16, 17, 20-heptol, 4, 9-epoxy-, 3-(2-methyl-2-butenoate) UF Veratrine Cevane-3, 4, 12, 14, 16, 17, 20-heptol, 4, 9-epoxy-, 3- (2) methy1-2-butenoate) U Cevadine CGMP U Guanosine 3',5'-cyclic monophosphate Chemoreceptors Chickens Chloralose 15879-93-3 693-07-2 Chlorfenvinphos BT Insecticides, organophosphate Chlorine cyanide U Cyanogen chloride N-Chloroacetyl-L-tyrosine ethyl ester U Acetyl-L-tyrosine ethyl ester 2-Chloroethyl ethyl sulfide 693-07-2 UF CEES

2-Chloroethyl ethyl sulfide 693-07-2

2-Chloroethyl ethyl sulfide 693-07-2 (cont'd) UF Ethyl 2-chloroethyl sulfide Bis(2-chloroethyl) sulfide U 2,2'-Dichloroethyl sulfide Bis(beta-chloroethyl) sulfide U 2,2'-Dichloroethyl sulfide Chloroform 67-66-3 Chloromercuribenzoates 2-Chloropromazine U Chlorpromazine Chlorpromazine 50-53-3 UF 2-Chloropromazine UF CPZ UF Promazil UF Thorazine Choline 62-49-7 NT Acetylthiocholine NT Benzoylcholine NT Butyrylthiocholine NT Phosphorylcholine NT Thiocholine NT Triethylcholine UF Bursine UF Ethanaminium, 2-hydroxy-N,N,N-trimethyl-UF Vidine #3H-Choline Choline acetylase U Acetyltransferase, choline Choline acetyltransferase U Acetyltransferase, choline Choline benzoate U Benzoylcholine Choling, benzoyl U Benzoylcholine Choline bromide 306-41-2 Choline carbamate chloride U Cartachol Choline chloride 67-48-1 Choline Cytidine 5'-pyrophosphate U Cytidine 5'-diphosphate choline Choline phosphate chloride U Phosphorylcholine Choline phosphoglycerides U Phosphatidylcholines Cholinergic agents U Parasympathomimetics Cholinergic blocking agents U Parasympatholytics Cholinergic receptors

Cholinergic receptors

Cholinergic receptors (cont'd) U Receptors, cholinergic Cholinesterase 9001-08-5 BT Esterases UF Benzoylcholinesterase UF Butyrylcholinesterase UF Esterase, choline UF Propionylcholinesterase UF Pseudocholinesterase Cholinesterase activity Cholinesterase inhibitors NT Ambenonium chloride NT Amiton NT Cholinesterase inhibitors, irreversible NT Cholinesterase inhibitors, reversible RT Insecticides UF Anticholinesterase activity UF Anticholinesterase agents Cholinesterase inhibitors, irreversible BT Cholinesterase inhibitors Cholinesterase inhibitors, reversible BT Cholinesterase inhibitors Cholinesterase Reactivators Cholinesterases NT ACHE Cholinoceptive sites U Receptors, cholinergic Cholinoceptors U Receptors, cholinergic Cholinolytics U Parasympatholytics Cholinomimetics U Parasympathomimetics Chondrosamine U Galactosamine Chondrosamine hydrochloride U Galactosamine hydrochloride Choroid plexus Chromatography Chromatography, column and liquid Chromatography, gas UF Gas chromatography Chromatography, gel UF Gel chromatography Chromatography, paper UF Paper chromatography Chromatography, thin-layer UF Thin-layer chromatography Chymar U Alpha-Chymotrypsin Alpha-Chymotrypsin 8049-46-5 9004-07-3 9025-29-0

Alpha-Chymotrypsin 8049-46-5 9004-07-3 9025-29-0 (cont'd) BT Peptide hydrolases UF Chymar UF Chymotrypsin-A Chymotrypsin-A U Alpha-Chymotrypsin Cinchocain U Dibucaine Cinchocaine U Dibucaine Cinchocaine hydrochloride 61-12-1 Circadian rhythm RT Periodicity Circulation U Blood circuition Citicholine U Cytidine 5'-diphosphate choline 1622-61-3 Clonazepas Cloning Cocaine 50-36-2 Cold RT Hypothermia Color U Binding, competitive

Alpha-Chymotrypsin

VILL STREET

Colorimetry Competitive binding Constriction Contracture Convulsions Cordycepin 73-03-0 Cosnegen U Actinomycin D Coumaphos BT Insecticides, organothiophosphate CPZ U Chlorpromazine Creatinine 60-27-5 CRO U Oscilloscope Crufomate BT Insecticides, organophosphate Crustacea CTP U Cytidine 5'-triphosphate Culture media Curare 8063-06-7 Cyanides Inorganic cyanides are indexed at Cyanides; organic cyanides, at Nitriles.

19

See.

Cyanogen bromide 506-68-3

,1

Cyanogen bromide 506-68-3 UF Bromine cyanide Cyanogen chloride 506-77-4 UF Chlorine cyanide Cyanogen iodide 506-78-5 UF Iodine monocyanide Cyanogen fluoride 1495-50-7 UF Fluorine cyanide Cvanomethane U Acetonitrile Cyanosis Cyclase, adenylate U Adenylate cyclase Cyclic AMP U Adenosine 3'5'-cyclic monophosphate Cyclic AMP-N6, 2'-O-dibutyrate U Dibutyryl cyclic AMP Cyclic GMP U Guanosine 3',5'-cyclic monophosphate Cyclic nucleotide phosphodiesterases BT Phosphodiesterases Cyclic nucleotides U Nucleotides, cyclic Cyclohexane 110-82-7 UF Hexamethylene Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-U Ketamine 5-Cyclohexenyl-3,5-dimethylbarbituric acid U Hexobarbital Cycloheximide 66-81-9 Cvclonal U Hexobarbital Cyclonal sodium U Hexobarbital sodium Cyclopentanecarboxylic acid, 1-phenyl-2 (diethylamino)ethyl ester U Caramiphen Cymography U Kymography Cytidine 65-46-3 UF 4-Amino-1-beta-D-ribofuranosyl-2-(1H) pyrimidinone UF Cytosine riboside Cytidine choline diphosphate U Cytidine 5'-diphosphate choline Cytidine cyclic monophosphate BT Cytosine nucleotides Cytidine diphosphate



21 Cytidine diphosphate (cont'd) BT Cytosine nucleotides Cytidine diphosphate choline U Cytidine S'-diphosphate choline Cytidine 5'-diphosphate choline 987-78-0 UF CDP-Choline UF Choline Cytidine 5'-pyrophosphate UF Citicholine UF Cytidine choline diphosphate UF Cytidine dipnosphate choline Cytidine 5'-diphosphate choline, monosodium salt 33818-15-4 Cytidine monophosphate BY Cytosine nucleotides Cytidine triphosphate BT Cytosine nucleotides 65-47-4 Cytidine 5'-triphosphate UF CTP Cytidine phosphates U Cytosine nucleotides Cytoplasm BT Cells Cytosine nucleotides NT Cytidine cyclic monophosphate NT Cytidine diphosphate NT Cytidine monophosphate NT Cytidine triphosphate phosphates UF Cytidine Cytosine riboside U Cytidine Dactinomycin U Actinomycin D DAM U 2,3-Butanedione, monooxime DDVP 62-73-7 UF 2,2-Dichlorovinyl dimethyl phosphate UF Dichlorvos UF Dimethyl-alpha, 2-dichlorovinyl phosphate UF 0,0-Dimethy1-0-(2,2-dichlorovinyl phosphate UF Phosphoric acid, esters, 2,2-dichloroethenyl dimethyl ester Dealkylation Death Death rate U Mortality 156-74-1 Decamethonium Defoliants, chemical U Herbicides

. .

ł

1 #

Ľ

٤.

Deformities BT Abnormalities Delacurarine U d-Tubocurarine chloride 8065-48-3 Demeton Dendrites BT Neurons Denervation (1-(2-deoxy-beta-D-erythropentofuranosyl)-5-methyl-2, 4(1H, 3H)-pyrimidinedione) U Thymidine 1-(2-Deoxy-beta-D-ribofuranosyl)-5-methyluracil Thymidine U Deoxyribonucleic acid UF DNA Dephosphorylation Depolarization Depression Dermal absorption U Skin absorption Detoxification Dextrose U Glucose DFF U DFP (Pesticide) 55-91-4 DFP (Pesticide) UF DFF UF Difluorophate UF Diisopropoxyphosphoryl fluoride UF Diisopropyl fluorophosphate UF Dyflos UF Fluorodiisopropyl phosphate UF Isofluorophate UF Phosphorofluoridic acid, bis (l-methylethyl) ester Diacetyl monoxime U 2,3-Butanedione, monooxime 17140-69-1 Diamethazole hydrochloride 136-96-9 Diamethazole dihydrochloride Diaphragm Diathermy RT Microwaves 439-14-5 Diazepam UF Valium UF 2H-1, 4-Benzodiazepin-2-one, 7-chloro-1, 3-dihydro-1-methyl-5-phenyl-333-41-5 Diazinon BT Insecticides, organothiophosphate UF Phosphorothioic acid, O, O-diethyl O-(2-isopropyl-6-methyl-4pyrimidinyl) ester

1

mer a firma and

محجود ومعوودة بمداد فالمح

22

Dibenyline U Dibenzyline Dibenzyline 59-96-1 UF Bensylyt UF Benzenemethanamine, N-(2-chloroethyl)-N-(1-methyl 2-phenoxyethyl)-UF Benzylyt UF Dibenyline UF Phenoxybenzamine Dibenzyline hydrochloride 63-92-3 UF Dibenzyline chloride UF Phenoxybenzamine chloride UF Phenoxybenzamine hydrochloride Dibucaine 85-79-0 **UF**Cinchocaine UF Cinchocain Dibucaine hydrochloride 61-12-1 Dibutyl 2,2-dichloroethenyl phosphate U 2,2-Dichlorovinyldibutylphosphate Dibutyl 2,2-dichlorovinyl phosphate U 2,2-Dichlorovinyldibutylphosphate Dibutyryl adenosine-3',5'-monophosphate U Dibutyryl cyclic AMP Dibutyryl cyclic adenosine monophosphate U Dibutyryl cyclic AMP Dibutyryl cyclic AMP 362-74-3 UF Adenosine, N-(1-oxobutyl)-, cyclic 3', 5' (hydrogen phosphate) 2'-butanoate UF Cyclic AMP-N6,2'-O-dibutyrate UF Dibutyryl 3',5'-cyclic AMP UF Dibutyryl adenosine-3',5'-monophosphate UF Dibutyryl cyclic adenosine monophosphate Dibutyryl 3',5'-cyclic AMP U Dibutyryl cyclic AMP 2,2-Dichloroethenyl diethyl phosphate U 2,2-dichlorovinyl diethyl phosphate 2,2-Dichloroethenyl dipropyl phosphate U 2,2-Dichlorovinyl dipropyl phosphate Di-2-chloroethyl sulfide U 2,2'-Dichloroethyl sulfide 2,2'-Dichloroethyl sulfide 505-60-2 UF Mustard gas UF Bis(2-chloroethyl) sulfide UF Bis(beta-chloroethyl) sulfide UF Di-2-chloroethyl sulfide 2,4-Dichlorophenyl methyl methylphosphonate 2,2-Dichlorovinyldibutylphosphate 18795-58-9 UF Dibutyl 2,2-dichloroethenyl phosphate UF Dibutyl 2,2-dichlorovinyl phosphate 2,2-dichlorovinyl diethyl phosphate 72-00-4 UF 2,2-Dichloroethenyl diethyl phosphate UF Ethyl DDVF

ŧ.

2,2-Dichlorovinyl diethyl phosphate 72-00-4 (cont'd) UF SD 1652
2,2-Dichlorovinyl dimethyl phosphate U DDVP
2,2-Dichlorovinyl Di-N-pentyl phosphate 20202-93-1 2,2-Dichlorovinyl diphenyl phosphate
2,2-Dichlorovinyl dipropyl phosphate 71-98-7 UF 2,2-Dichloroethenyl dipropyl phosphate
2,2-Dichlorovinyl methyl pentyl phosphate 34622-69-0 Dichlorvos
U DDVP
Diethylaminoacetyl-N-phenothiazine hydrochloride U Difazin
2-Diethylaminoethylbenzylate hydrochloride U Benactyzine
2-Diethylaminoethyl diphenyl acetate hydrochloride U Trazentine
2-Diethylaminoethyl-L-phenyl cyclopentane carboxylate hydrochloride
U Caramiphen hydrochloride
N-(3-Diethylaminopropyl)-2-2-diphenylacetamide U Arpenal
3-Diethylaminopropyl oximinoacetate 25057-76-6 UF OAB
l,4-Diethylene dioxide
U Dioxane
Diethyl-p-nitrophenyl phosphate U Paraoxon
Diethyl p-nitrophenyl phosphorothionate U Parathion
Diethyl p-nitrophenylthionophosphate U Parathion
Diethyl p-nitrophenylthiophosphate U Parathion
Diethylphosphorylfluoride
Diethyl-S-2-diethylaminoethyl phosphorothioate

A second s

24

. .

•••

]:

`*.` _ I

O, O-Diethyl S-2-diethylaminoethyl phosphorothioate U Amiton Difacil hydrochloride U Trasentine hydrochloride 641-33-8 Difazin UF 10H-Phenothiazine, 10 [(diethylamino)-acetyl] UF Diethylaminoacetyl-N-phenothiazine hydrochloride Difluorophate U DFP (Pesticide) Difonate BT Insecticides, organothiophosphate Digestive system 1, 3-Dihydro-7-nitro-5-phenyl-2H-1, 4-benzodiazepin-2-one U Nitrazepam 7'12'-Dihydroxy-6, 6'-dimethoxy-2, 2', 2'-trimethyltubocuraranium chloride U d-Tubocurarine chloride Dihydroxyphenylalanine U DOPA Diisopropoxyphosphoryl fluoride U DFP (Pesticide) Diisopropyl fluorophosphate U DFP (Pesticide) N-N'-Diisopropylphosphorodiamidic anhydride U DPDA N. N'-Diisopropylphosphorodiamidic fluoride U Mipafox Diisopropylphosphorofluoridase U Tabunase Diisopropyl phosphorofluoridate U Isofluorophate Dibenzyline chloride U Dibenzyline hydrochloride Dimefox 115-26-4 UF Phosphorodiamide fluoride, tetramethyl-1,1-Dimethyl-4-phenylpiperazinium iodide U DMPP Dimethoate 60-51-5 UF Phosphamide UF Phosphorodithionic acid, esters, O, O-dimethyl S-[2-(methylamino)-2oxoethyl] ester Dimethoxy p-nitrophenoxyphosphine oxide

Dimethoxy p-nitrophenoxyphosphine oxide

.....

. .

. .

ومعارية والمراجع

```
Dimethoxy p-nitrophenoxyphosphine oxide (cont'd)
    U DMPA
3,4-Dimethoxy-L-phenylalanine
    U DMPA
Dimethylamidoethoxyphosphoryl cyanide
    U Tabun
Dimethylamine 124-40-3
   UF Methanamine, N-methyl-
3-(2-Dimethyl-aminoethyl) phenyl-N-methylcarbamate
2,3-Dimethy1-2-butanol
                       594-60-5
   UF Isopropyldimethylcarbinol
3,3-Dimethyl-2-butyl-methyl-phosphonofluoridate
    U Soman
Dimethyl carbamate
                       39589-98-5
1,5-Dimethyl-5-(1-cyclohexenyl) barbituric acid
    U Hexobarbital
0,0-Dimethyl-O-(2,2-dichlorovinyl phosphate
   U DDVP
Dimethyl-alpha, 2-dichlorovinyl phosphate
    U DDVP
1,2-Dimethyl-3-diethylaminopropyl p-isobutoxybenzoate
    U Gangleron
N,N-Dimethylformamide
                          69-12-2
   UF DMF
   UF DMFA
   UF Formamide, N, N-dimethyl-
1,1-Dimethyl-2-phenylaziridinium
   UF DPA
Dimethylphenylpiperazinium
   U DMPP
N-Dimethylphosphoramidocyanidate
   U Tabun
Dimethylphosphoramidocyanidic acid, ethyl ester
   U Tabun
Dimethylphosphorylfluoride
Dimethyl sulfoxide 67-68-5
   UF DMSO
Dimethyltubocurarine
   U Dimethy1-D-tubocurarine
Dimethyl-D-tubocurarine 35-67-6
   UF Dimethyltubocurarine
Dimethyl-D-tubocurarine chloride
                                    518-25-2
  UF Dimethylturocurarine chloride
Dimethyl tubocurarine iodide 518-26-3 7601-55-0
   UF Metocurine iodide
Dimethylturocurarine chloride
   U Dimethyl-D-tubocurarine chloride
Dimetilan 644-64-4
```

Dimetilan 644-64-4 Dimetilan 644-64-4 (cont'd) UF Dimetilane Dimetilane U Dimetilan Di methylphenylpiperazinium iodide U DMPP Dina 4185-47-1 UF Ethanol, 2, 2'-(nitroimino) bis-, dinitrate (ester) Dinitrogen monoxide U Nitrous oxide 2,4-Dinitrophenol 51-28-5 Dioisopropylphosphoric acid Diophenylacetic acid diethylaminopropylamide U Arpenal 123-91-1 Dioxane UF 1,4-Diethylene dioxide Dioximes UF Oximes, di-Diphosphoramide, octamethyl-U Octamethyl pyrophosphoramide Diphosphoric acid tetreaethyl ester U Tetraethyl pyrophosphate Dipterex U Trichlorfon Disodium thiosulfate U Sodium thiosulfate Disulfoton BT Insecticides, organothiophosphate Dithionates DMF U N.N-Dimethylformamide DMFA U N, N-Dimethylformamide DMPA 32161-30-1 UF Dimethoxy p-nitrophenoxyphosphine oxide UF 3,4-Dimethoxy-L-phenylalanine 299-85-4 DMPA (herbicide) UF Phosphoramidothioic acid, (1-methylethyl)-O-(2,4 dichlorophenyl)-O-methyl ester UF Zytron DMPP 54-77-3 BT Piperazines UF 1,1- Dimethyl-4-phenylpiperazinium iodide UF Dimethylphenylpiperazinium UF Dimethylphenylpiperazinium iodide UF Piperazinium, 1,1-dimethyl-4-phenyl-, iodide DMSO U Dimethyl sulfoxide DNA U Deoxyribonucleic acid

27

. . .



Dogs

Dogs BT Laboratory animals BT Mammals DOPA 59-92-7 UF Dihydroxyphenylalanine Dorsal muscles Dosage forms Dose-response relationship RT Immunity 309-29-5 Doxapram DPA U 1,1-Dimethyl-2-phenylaziridinium DFDA 513-00-8 UF N-N'-Diisopropylphosphorodiamidic anhydride UF fetraisopropyl pyrophosphoramide Drug therapy DSDP U Amiton Dyes Dyflos U DFP (Pesticide) Dyspnea E-600 U Paraoxon Ear BT Sense organs Eccrine glands BT Sweat glands Echothiophate iodide 513-10-0 UF Ecothiopate iodide UF Phospholine iodide Echothiophate 6736-03-4 UF Ecothiopate UF MI-217 UF Phospholine Ecothiopate U Echothiophate Ecothiopate iodide U Echothiophate iodide Edem UF O-Ethyl-S-(2-diethylamiroethyl)methyl thiophosphonate Edetic acid **U** EDTA Edrophone bromide U Edrophonium bromide Edrophonium 312-48-1 UF Benzenaminium, N-ethyl-3-hydroxy-N,N-dimethyl-Edrophonium bromide 302-83-0

Edrophonium bromide 302-83-0

Edrophonium bromide 302-83-0 (cont'd) UF Edrophone bromide UF Ethyl(m-hydroxyphenyl)dimethylammonium bromide UF N-Ethyl-3-hydroxy-N,N-dimethylbenzenaminium bromide UF Tensilon bromide Edrophonium chloride 116-38-1 UF Antirex UF Tensilon chloride EDTA 60-00-4 64-02-8 UF Edetic acid UF Ethylenediaminetetraacetic acid Eel Electric stimulation UF Stimulation, electric Electrodes Electrodes, implanted Electrophoresis Enbryo Enantiomerism and Enantiomers UIsomerism and Isomers, optical Endocid U Endothion Endocide U Endothion Endocrine glands NT Adrenal glands NT Islands of Langerhans NT Parathoid glands NT Pineal body NT Pituitary gland NT Pituitary-adrenal system NT Thyroid gland Endocrine system Endothion 2778-04-3 UF Endocid UF Endocide Endplate Enzymatic phosphorylation Enzyme activation Enzyme inhibitors Enzyme reactivators Enzyme repression Enzymes Epinephrine 51-43-4 UF Adrenaline Epithelial cells BT Cells Epithelium EPN 2104-64-5 BT Insecticides, organothiophosphate UF Phosphonothioic acid, phenyl-O-ethyl O-(4 nitrophenyl)ester Equilibrium

29

i

1.

1

T

ţ

13

b

١.,

Ergamine U Histamine Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6 methy1-, (88)-U LSD Ergotidine U Histamine Erythroblasts BT Erythrocytes Erythrocytes BT Blood cells NT Erythroblasts RT Reticulocytes UF Red blood cells Erythrocyte volume, packed U Hematocrit Erythropoiesis 11096-26-7 Erythropoietin BT Glycoproteins Eserine U Physostigmine 9016-18-6 Esterase, carboxyl BT Esterases UF Aliesterase Esterase, choline U Cholinesterase Esterases BT Hydrolases NT Cholinesterase NT Esterase, carboxyl Esters Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-U Acetylcholine Ethanaminium, 2-(benzoyloxy)-1 N, N-trimethyl-U Benzoylcholine Ethanaminium, 2-hydroxy-N,N,N-trimethyl-U Choline 2-(benzoyloxy)-N,N,N-trimethyl-Ethanaminium U Benzaylcholine Ethanaminium, 2-mercapto-N,N,N-trimethyl-U Thiocholine Ethanol 64-17-5 UF Alcohol, ethyl Ethanol,2,2'-(nitroimino)bis-,dinitrate (ester) U Dina Ethion BT Insecticides, organothiophosphate

٠

Ethoxy-

Ethoxy-2-dimethylamino-ethylthiomethyl-phosphine oxide U Medemo Ethoxy-2-ethylthioethyl-thiomethyl-phosphine oxide U GD-7 Ethoxy-2-ethylthioethyl-thicmethyl-phosphin oxide methyl sul fomethyl ate U GD-42 Ethoxy group (2-((Ethoxymethylphosphinyl)thip)ethyl)ethylmethyl sulfonium methyl sulfate U GD-42 Ethoxy-4-nitrophenyloxy-ethylphosphynoxide U Armin Ethyl acetyltyrosinate U N-Acetyl-L-tyrosine ethyl ester Ethyl N-acetyl-L-tyrosinate U Acety1-L-tyrosine ethyl ester N-Ethyl-8-aza-3-bicyclo [3.2.1.]octyl benzhydryl ether U Ethylbenztropine 524-83-4 Ethylbenztropine UF N-Ethyl-8-aza-3-bicyclo [3.2.1. Joctyl benzhydryl ether UF N-Ethylbenztropine UF N-Ethylnorthropane benzhydrine ether hydrochloriae UF Ponalid N-Ethylbenztropine U Ethylbenztropine Ethyl carbamate U Carbamic acid, esters, ethyl ester Ethyl 2-chloroethyl sulfide U 2-Chloroethyl ethyl sulfide Ethyl DDVP U 2,2-dichlorovinyl diethyl phosphate Ethyl dimethylamidocyanophosphate U Tabun Ethyl dimethylphosphoramidocyanidate U Tabun Ethyl N,N-dimethyl phosphoramido cyanidate U Tabun Ethylenediaminetetraacetic acid U EDTA Ethyl guthion 2642-71-9 N-Ethyl-3-hydroxy-N,N-dimethylbenzenaminium bromide U Edrophonium bromide Ethyl methylphosphonothiothiolic acid Ethyl (m-hydroxyphenyl) dimethylammonium bromide U Edrophonium bromide Ethyl p-nitrophenyl ethylphosphonate U Armin Ethyl 4-nitrophenyl methylphosphonate 3735-98-6

31

1

17

Į.

N-Ethylnorthropane

N-Ethylnorthropane benzhydrine ether hydrochloride U Ethylbenztropine Ethyl paraoxon U Paraoxon Ethyl parathion U Parathion Ethyl phosphoric acid U Phosphoric acid, esters, ethyl ester N-Ethyl-2-pyrrolidylmethyl phenylcyclopentylglycolate hydrochloride U PMCG O-Ethyl S-diethylaminoethyl ethylphosphonothiolate 21738-25-0 O-Ethyl, S-diethylaminoethyl-ethylphosphonothiolate U AM-1 O-Ethy1-S-(2-diethy1aminoethy1)methy1 thiophosphonate U Edem D-Ethyl 5-(2-diisopropylaminoethyl methylphosphonothioate 50782-69-9 UF D-Ethyl S-(2-diisopropylaminoethyl) methylthiophosphonate O-Ethyl S-(2-diisopropylaminoethyl) methylthiophosphonate U O-Ethyl S-(2-diisopropylaminoethyl methylphosphonothioate Ethyl-S-(2-diisopropylaminoethyl) methylthiophosphonate u vx J-Ethyl S-(beta-ethylthioethyl) methylphosphonothioate U GD-7

•

Exocrine glands RT Pancreas

. .

T

Ľ

Experimental design U Research design Exposure, chambers, inhalation U Inhalation chambers Eye BT Sense organs Eyelids RT Nictitating membrane

Face Fasciculation Involuntary contractions,, or twitchings, of groups of muscle fibers Fasciculus Fatty acids Fatty acids, unsaturated Femoral artery Femoral nerve Femoral vein Femur Fensulfothion BT Insecticides, organothiophosphate 7705-08-0 Ferric chloride Ferrohemoglobin U Hemoglobins Fever RT Body temperature UF Hyperthermia Fibrillation Flexor Flowmeters Fluorescence Fluorides Term used for fluorides as a class. Specific terms are used to index subclasses. Fluorine 7782-41-4 BT Halogens Fluorine cyanide U Cyanogen fluoride Fluorodiisopropyl phosphate U DFP (Pesticide) Fluoromethyl sulfone U Methanesulfonic fluoride Fluoromethyl(1,2,2-trimethylpropoxy) phosphine oxide U Soman Fluorometry Foot Forearm BT Arm Forelimb 50-00-0 Formaldehyde Formamide, N,N-dimethyl-U N, N-Dimethylformamide Formothion BT Insecticides, organothiophosphate 1,3-bis(4-formylpyridinium-propane)bis-oxime dichloride U B4FPBOC12 Frogs 6 2747 U Caramiphen hydrochloride GABA 56-12-2 UF Butanoic acid, 4-amino

22

. .

. .

- -

. -

GABA

1

12

• •

...

. .

GABA (cont'd) UF gamma-aminobutyric acid GABA-T UF GABA transamininase GABA transamininase U GABA-T GAD UF Glutamic acid decarboxylase 1948-54-5 Galactosamine UF Chondrosamine UF Galactose, 2-amino-2-deoxy-Galactosamine hydrochloride UF Chondrosamine hydrochloride Galactose, 2-amino-2-deoxy-U Galactosamine 1510-29-8 Gangleron UF 1,2-Dimethyl-3-diethylaminopropyl pisobutoxybenzoate UF Benzoic acid, 4-(2-methylpropoxy)-3 (diethyl; ino)-1,2-dimethylpropyl ester hydrochloride UF Ganglerone Ganglerone U Gangleron Ganglia Ganglia, parasympathetic UF Parasympathetic ganglia Ganglia, spinal BT Spinal nerve roots Ganglia, sympathetic UF Sympathetic ganglia Ganglionic blockaders UF Ganglionic blocking agents UF Ganglioplegic agents Ganglionic blocking agents U Ganglionic blockaders Ganglionic stimulants UF Nicotinic agents Ganglioplegic agents U Ganglionic blockaders Gas chromatography U Chromatography, gas Gastric emptying Gastric probe Gastrocnemius muscle BT Muscles Gastrointestinal hemorrhage UF Hemorrhage, gastrointestinal Gastrointestinal system NT Intestines

NT Stomach

35 GD-42 2562-54-1 UF (2((Ethoxymethylphosphinyl)thio)ethyl)ethylmethyl sulfonium methyl sulfate UF Ethoxy-2-ethylthioethyl-thiomethyl-phosphin oxide methylsulfomethylate UF Phosphonothioic acid, methyl-, O-ethyl ester UF Sulfonium, [2-[(ethoxymethylphosphinyl)thio]ethyl]methyl-, methyl sulfate GD-7 556-75-2 UF Ethoxy-2-ethylthioethyl-thiomethyl-phosphine oxide UF O-Ethyl S-(beta-ethylthioethyl)methylphosphonothioate UF Phosphonothioic acid, methyl-, O-ethyl S-[2(ethylthio)ethyl] ester Geiger Counter RT Radiometry UF Geiger-Mueller Counter Geiger-Mueller Counter U Geiger Counter Gel chromatography U Chromatography, gel Germ cells Gills Globus pallidus Glucose 50-99-7 UF Dextrose UF D-Glucose D-Glucose U Glucose Glutamic acid 6899-05-4 DL-Glutamic acid 617-65-2 L-Glutamic acid 56-86-0 Glutamic acid decarboxylase U GAD Glutamic oxalacetic transaminase 9000-97-9 UF Aminotransferase, aspartate UF GOT Glycemia Glycoproteins NT Erythropoietin GMP U Guanosine monophosphate 3, 5-GMP U Guanosine 3', 5'-cyclic monophosphate GOT U Glutamic oxalacetic transaminase Growth Growth inhibitors G-Strophanthin U Ouabain

Guanosine

. .

- -

Guanosine 3',5'-cyclic monophosphate 7665-99-8 UF 3,5-GMP UF' CGMP UF Cyclic GMP Guanosine monophosphate UF GMP Guinea pigs BT Laboratory animals BT Mammals Gusathion M U Guthion Guthion 86-50-0 UF Azinphos-methyl UF Gusathion M Gyrus, frontalis superior Gyrus, post centralis Gyrus, precentralis $^{3}\mathrm{H}$ Hair U Tritium Half-life Halogens NT Fluorine Hamsters BT Mammals Hand Hazards ΗЪ U Hemoglobins HC-3 312-45-B UF Morpholinium, 2,2°[1,1-biphenyl]-4,4'-diylbis [2 hydroxy-4,4-dimethyl-, dibromide-Head Heart Heart arrest UF Cardiac arrest Heart block UF Atrioventricular block Heart failure, congestive Heart function tests Heart rate Heart ventricle Heat Heating Heat loss U Body temperature regulation Heat production U Body temperature regulation Hematocrit UF Erythrocyte volume, packed Hemicholinium 16478-59-4 UF Morpholinium, 2,2'-[1,1'-biphenyl] 4,4'-diylbis [2-hydroxy-4,4-dimethyl-

36

į.

Hemicholinium-3

312-45-8 Hemicholinium-3 UF Morpholinium, 2,2' [1,1'-biphenyl]4,4'-diylbis [2-hydroxy-4,4-dimethyl-, dibromide Hemocytes ST Blood cells Hemoglobins UF Ferrohemoglobin UF Hb Hemolysins UF Hemotoxins Hemolysis Hemorrhage Hemorrhage, cerebral U Cerebral hemorrhage Hemorrhage, gastrointestinal U Gastrointestinal hemorrhage Hemotoxins U Hemolysins Hens 9005-49-6 Heparin UF Heparinic acid Heparinic acid U Heparin Herbicides UF Defoliants, chemical Hering-Breuer Reflex Hexamethonium 60-26-4 UF 1,6-Hexanediaminium, N,N,N,N',N',N'-hexamethyl-55-97-0 Hexamethonium bromide 60-25-3 Hexamethonium chloride 870-62-2 Hexamethonium iodide UF 1,6-Hexanediaminium, N,N,N,N',N',N'-hexamethyl-, diiodide 110-82-7 Hexamethylene U Cyclohexane 1,6-Hexanediaminium, N,N,N,N',N',N'-hexamethyl-U Hexamethonium 1,6-Hexanediaminium, N,N,N,N',N',N'-hexamethyl-, diiodide U Hexamethonium iodide Hexobarbital 56-29-1 630-97-7 UF 1,5-Dimethyl-5-(1-cyclohexenyl) barbituric acid UF 5-Cyclohexenyl-3,5-dimethylbarbituric acid UF Cyclonal UF Hexobarbitone Hexobarbital sodium 50-09-9 UF Cyclonal sodium UF Hexobarbital soluble UF Hexobarbitone sodium UF Sodium hexobarbital UF Sodium hexobarbitone

37

.

1.

É

- second a

and the second



Hexobarbital soluble

Ti

```
Hexobarbital soluble
    U Hexobarbital sodium
Hexobarbitone
    U Hexobarbital
Hexobarbitone sodium
    U Hexobarbital sodium
Hexokinase
HI-6 34433-31-3
    UF Pyridinium, 1-CCC4
    aminocarbonylpyridinioJmethoxyJmethyll -2
    [hydroxyimino)methyl]-dichloride
Hip
Hippocampus
Histamine
              51-45-6
    UF 1H-Imidazole-4-ethanamine
    UF 2-(4-Imidazolyl)ethylamine
    UF 4-Imidazoleethylamine
    UF beta-Aminoethylglyoxaline
    UF Ergamine
    UF Ergotidine
    UF Theramine
Histology
    NT Histopathology
Histopathology
    BT Histology
    BT Pathology
HNB-3
    U Quinuclidinyl benzilate hydrochloride
Homeostasis
Homogenates
Harmones
    For studies of hormmones as a class. For specific
    hormones, use specific terms.
Horse serum
HS-3 25487-36-9
    UF Pyridinium, 2-Chydroxyimino) methyl 3-1- [[[4-
    [(hydroxyimina) methyl] pyridinio] methoxy] methyl]
    , dichloride
HS-6 22625-23-6
    UF N,N'-Oxydimethylene-bis (pyridinium-2-aldoxime-3
    carboxamido)
    UF Pyridinium, 1-EEE3-(aminocarbonyl)
    pyridinioJmethoxyJ methylJ -2-[(hydroxyimino)
    methyl] -, dichloride
Hydrazine, phenyl
    U Phenylhydrazine
Hydrofluoric acid 7664-39-3
    UF Hydrogen fluoride
Hydrogen
            1333-74-0
```

Hydrogen-3 U Trit:um Hydrogen fluoride U Hydrofluoric acid Hydrogen, isotopes of NT Tritium Hydrolases NT Esterases NT Peptide hydrolases NT Phosphatases Hydrolysis Hydroxyimino compounds U Cximes Hydroxyimino group 2-Hydroxyiminomethyl-1-methylpyridinium 154-97-2 51729-73-8 methanesulfonate U P2S bis(4-hydroxyiminomethyl-pyridinium- 1-methyl)- ether dichloride U Toxogonin Beta-Hydroxylalanine U Serine Hydroxyl greup alpha-(Hydroxymethyl)benzeneacetic acid U Tropic acid Tris (hydroxymethyl) methanamine U Tris buffer 7-Hydroxyquinoline 580-20-1 Hydroxyquinolines Hyoscine U Scopolamine Hyoscyamine 101-31-5 U Atropine Hyperglycemia RT Blood glucose Hypersensitivity RT Allergens RT Allergy RT Anaphylaxis **RT Immunity** RT Immunology RT Sensitization Hypertension UF Blood pressure, high Hyperthermia U Fever Hypnotics and Sedatives NT Barbiturates

Hydrogen-3

39

ŧ

ŧ

3.1.4

Hypnotics and Sedatives

Hypnotics and Sedatives (cont'd) NT Sedatives, Nonbarbiturate RT Tranquilizing agents **UF** Sedatives Hypo U Sodium thiosulfate Hypotension UF Blood pressure, low Hypothalamus Hypothermia RT Cold Hypoxia U Anoxia Ileum 288-32-4 Imidazole 1H-Imidazole-4-ethanamine U Histamine 1H-Imidazole-1-ethanol, alpha-(methoxymethyl)-2-methyl 4-nitro-U AM-1 4-Imidazoleethylamine U Histamine 28299-33-4 Imidazoline 2-(4-Imidazolyl)ethylamine U Histamine Immobilization Immunity NT Antibody diversity NT Antibody formation NT Antibody specificity NT Antigen-antibody reactions NT Immunity, natural NT Immunity, passive RT Dose-response relationship RT Hypersensitivity RT Receptors, immunologic Immunity, natural BT Immunity Immunity, passive BT Immunity Immunization Immunology RT Hypersensitivity Incubation 1H-Indol-3-ol U Indoxyl Indophenol acetate U Indophenyl acetate Indophenyl acetate 7761-80-0 UF Indophenol acetate Indoxy1 480-93-3 UF 1H-Indol-3-ol

Indoxyl acetate

41

Indoxyl acetate 608-08-2 UF 3-Acetoxyindole Induction Inferno U Amiton Inflammation Infrared spectra

Infrared spectrometry Inhalation BT Breathing Inhalation chambers UF Exposure, chambers, inhalation Inhalation tests Inhalation toxicity Inhibition Inhibition, neural U Neural inhibition Inhibitor Inhibitor Injuries

Insecticides

NT Amiton

NT Insecticides, organophosphate

NT Insecticides, organothiophosphate

NT Malathion

RT Cholinesterase inhibitors

Insecticides, carbamate

NT Aldicarb

. .

. .

÷ .

Ľ

~

Insecticides, organophosphate

BT Insecticides

- NT Chlorfenvinphos
- NT Crufomate
- NT Mevinphos
- NT Monocrotophos
- NT Naled
- NT Phosphamidon

Insecticides, Organophosphate

RT Organophosphorus compounds

Insecticides, organothiophosphate

- BT Insecticides
- BT Organothiophosphorus compounds

۰.

NT Abate

NT Azinphosmethyl

- NT Bromophos
- NT Coumaphos
- NT Diazinon
- NT Difonate
- NT Disulfcton

Insecticides, organothiophosphate (cont'd) NT EPN NT Ethion NT Fensulfothion NT Formothion NT Methyl mercaptophos NT Phorate NT Phosmet NT Phosvel NT Thiometon Interneurons BT Neurons Interrenal gland BT Adrenal glands Intestines BT Gastrointestinal system Intoxication Intracranial pressure RT Skull 7553-56-2 Iodine Iodine monocyanide U Cyanogen iodide Ionization Ions Irradiation Irritation RT Primary irritancy Ischemia RT Blood circulation Islands of Langerhans BT Endocrine glands UF Pancreas, endocrine Isoamyl acetate 123-92-2 UF Amylacetic ester Isofluorophate U DFP (Pesticide) 119-38-0 Isolan Isomerism and Isomers, optical UF Enantiomerism and Enantiomers Isomerism and Isomers UF Stereoisomerism and Stereoisomers Isonitrosoacetone U MINA Isonitroso compounds U Oximes

۰.

11

Iso-OMPA

and a second of a second se

43

٦

. ..

. .

. .

--

--

• •

[]

1

F

]

Second States

いたいている ちょうかん たいがましたの

513-00-8 ISO-OMPA Isoprenaline U Isoproterenol Isopropanol U 2-Propanol Isopropoxymethylphosphoryl fluoride U Sarin Isopropyl alcohol U 2-Propanol Isopropyldimethylcarbinol U 2,3-Dimethyl-2-butanol Isopropyl methyl fluorophosphonate U Sarin Isopropyl methyl phosphonofluoridate U Sarin Isoproterenol 7683-59-2 UF Isoprenaline 126-75-0 Isosystox JB-336 3321-80-0 UF Benzeneacetic acid, alpha-hydroxy-alpha-phenyl esters, 1-methyl-3-piperidinyl ester UF N-Methyl-3-hydroxypiperidine benzilate UF N-Methyl-3-piperidinyl benzilate JB-336/3 3689-80-3 UF Benzeneacetic acid, alpha-hydroxy-alpha-phenyl-, esters, 1-methyl-3-piperidinyl esters, hydrochloride UF N-Methylpiperidylbenzilate, hydrochloride JB-336/4 29568-43-0 UF Benzeneacetic acid, alpha-hydroxy-alpha-phenyl-, esters, 1-methyl-4-piperidinyl ester, hydrochloride UF N-Methyl-4-piperidyl benzilate hydrochloride UF N-Methyl-4-piperidyl diphenylglycolate hydrochloride Joints Jugular' veins 6740-88-1 Ketamine UF Cyclohexanone, 2-(2-chlorophenyl)-2 (methylamino)-Kidney BT Urinary tract Kinetics Knee Kymography UF Cymography

and the second second LA-1 44 LA-1 U Nitrazepam Laboratory animals BT Animals NT Cats NT Dogs NT Guinea pigs NT Mice NT Monkeys NT Rabbits NT Rats RT Animal testing UF Animals, laboratory Lacunae Lanthanum 7439-91-0 LD50 NT Lethal dose UF Lethal dose 50 Lecithins General term. Use name of specific lecithins where indicated. UF Lecithol UF Phosphatidylcholines Lecithol U Lecithins Leeches Leg Lethal dose BT LD50 Lethal dose 50 U LD50 Leucine 7005-03-0 UF 2-Amino-4-methylvaleric acid UF alpha-Aminoisecaproic acid DL-Leucine 328-39-2 L-Leucine 61-90-5 Leukocytes BT Blood cells UF White blood cells Lidocaine 137-58-6 UF Lignocaine UF Xylocaine Ligaments Ligands Lignocaine U Lidocaine Ligroin 8032-32-4 UF Patroleum ether

- ----

1

Limbic system

Limbic system Limbs Lip Lipids NT Membrane lipids Liver LSD 50-37-3 UF Ergoline-8-carboxamide, 9,10-didehydro-N,N diethyl-6-methyl-, (88)-UF Lysergic acid diethylamide UF Lysergide LuH-6 U Toxogonin Lung NT Bronchi NT Pulmonary alveoli RT Air sacs **RT** Respiration Lymph Lymphatic system Lymph nodes Lysergic acid diethylamide U LSD Lysergide U LSD Lysocythins U Lysolecithins Lysolecithins For lysolecithins as a class. Prefer specific lysolecithins. UF Lysocythins UF Lysophosphatidylcholines Lysophosphatidylcholines U Lysolecithins Macaca Mulatta U Monkey, Rhesus 7439-95-4 Magnesium Magnesium chloride 7786-30-3 Magnesium sulfate 7487-88-9 Malaoxon U Malathion Malathion 121-75-5 BT Insecticides UF Butanedioic acid . [Dimethoxyphosphinothioy1) thiol-, diethyl ester UF Malaoxon

Mammals BT Vertebrates NT Cats NT Dogs

45

2 S

*

] [

Mammals (cont'd) NT Guinea pigs NT Hamsters Mice NT NT Primates Rabbits NT NT Rats 7439-96-5 Manganese Manometry RT Pressure Marmosets U Callithricidae Marrow U Bone marrow Mass spectra Mass spectrometers and spectrographs Mass spectrometry U Mass spectroscopy Mass spectroscopy UF Mass spectrometry Maximal voluntary ventilation BT Respiratory air flow Mecamine U Mecamylamine 60-40-2 Mecamylamine UF Mecamine UF Bicyclo [2.2.1] heptan-2-amine, N,2,3,3,tetramethyl-UF N,2,3,3-Tetramethylbicyclo 2.2.1 heptan-2-amine UF Versamine Mecholin U Methacholine bromide Mecholyl bromide U Methacholine bromide 51366-09-7 Medemo UF Ethoxy-2-dimethylamino-ethylthiomethyl-phosphine oxide UF Phosphonothioic acid, methyl-, S-[2-[(dimethylamino)thio] ethy1] 0-ethy1 ester Medulla oblongata Methylnorepinephrine U Norepinephrine Membrane lipids BT Lipids Membrane potentials RT Cell membrane RT Membranes Membranes Cell membrane RT Membrane lipids RT RT Membrane potentials 25990-43-6 Mepenzolate

. 1

Mepenzolate bromide 76-90-43 UF N-Methyl-3-piperidyl benzilate methyl bromide Meractinomycin U Actinomycin D 2-Mercaptoethyl sulfide U TDT (2-Merceptoethyl)trimethylammonium iodide butyrate U Butyrylthiccholine iodide Mestinon 101-26-8 UF Mestinon bromide UF Pyridostigmine bromide Mestinon bromide U Mestinon Mesyl fluoride Methanesulfonic fluoride U Metabolic detoxication, drug Metabolic inhibitors Metabolism NT Anaerobiosis Metabolites Methacholine 55-92-5 1-Propanaminium, 2-(acetyloxy)-N,N,N-trimethyl-UF UF Acetyl-beta-methylcholine Methacholine bromide 333-31-3 UF 1-Propanaminium, 2-acetyloxy)-N,N,N-trimethyl-, bromide UF Acetyl-beta-methylcholine bromide UF Amechol UF Mecholin Mecholyl bromide UF Methachcline chloride 62-51-1 1-Propanaminium, 2 (acetyloxy)-N,N,N-trimethyl chloride UF UF Acetyl-beta-methylcholine chloride Methacholine iodide 625-19-4 Methanamine, N-methyl-U Dimethylamine Methanesulfonic fluoride 558-25-8 UF Fluoromethyl sulfone UF Mesyl fluoride UF MSF UF Methylsulfonyl fluoride 67-56-1 Methanol UF Alcohol, methyl Methionine 7005-18-7 59-51-8 DL-Methionine 63-68-3 L-Methionine 1-Methy1-2-aldoximinopyridinium chloride 2-PAM chloride U 287-07-15 Methylatropine 2870-71-5 Methylatropine bromide

A LA MARKED AND A MARKED

Methylatropine bromide 2870-71-5

```
Methylatropine bromide 2870-71-5 (cont'd)
UF Atropine methyl bromide
UF 8-Azoniabicyclo [3.2.1] octane, 3-(3-hydroxy-1
oxo-2-phenylpropoxy)-8,8-dimethyl-, bromide, endo-
Methylatropine nitrate 52-88-0
UF 8-Azoniabicyclo [3.2.1] octane, 3-(3-hydroxy-1
oxo-2-phenylpropoxy)-8,8-dimelthyl-, endo-, nitrate
N-Methyl carbamate 63-25-2
UF 1-Naphthalenol, methylcarbamate
UF Carbary1
UF Sevin
Methyl cyanide
U Acetonitrile
```

N,N'-bis (1-methylethyl)phosphorodiamidic fluoride U Mipafox Methyl glycol U alpha-Propylene glycol Methyl group

N-Methyl-3-hydroxypiperidine benzilate U JB-336 Methyl isopropoxy phosphoryl fluoride U Sarin Methyl mercaptophos BT Insecticides, organothiophosphate Methyl parathion 298-00-0 Tris (o-methylphenyl) phosphate U Tri-o-tolyl phosphate Methyl phosphonate U Phosphonic acid, dimethyl ester Methylphosphonic acid U Phosphonic acid, methyl-Methylphosphonofluoridates Methylphosphonofluoridic acid, 1-methylethyl ester U Sarin Methylphosphonofluoridic acid 1,2,2-trimethylpropyl ester U Soman Methylphosphonofluoridic acid 1,2,2-trimethyl propyl ester U Soman Methyl pinacolyloxy phosphoryl fluoride U Soman Methyl pinacolyl phosphonofluoridate U Soman N-Methyl-3-piperidinyl benzilate U JB-336 N-Methylpiperidylbenzilate, hydrochloride U JB-336/3

N-Methyl-4-piperidyl benzilate hydrochloride

N-Methyl-4-piperidyl benzilate hydrochloride U JB-336/4

```
N-Methyl-4-piperidyl diphenylglycolate hydrochloride
    U JB-336/4
1-Methylpyridinium-2-aldoxime methanesulfonate
    U P2S
N-Methylpyridinium-2-aldoxime methane sulfonate
    U P2S
N-Methyl pyridinium-2-aldoxime trichloroacetate
Methylpyridinium iodide 61734-40-5 930-73-4
    UF Pyridine methiodide
                       13265-10-6
Methylscopolamine
    UF Scopolamine methyl bromide
                              18905-44-7
Methylscopolamine bromide
    UF Scopolamine methyl bromide
Methylsulfonylfluoride
    U Methanesulfonic fluoride
Metocurine iodide
    U Dimethyl tubocurarine iodide
Metramac
    U Amiton
Mevinphos
    BT Insecticides, organophosphate
 Mevinphos
    U Phosdrin
MI-217
    U Echothiophate
Mice
    BT Laboratory animals
    BT Mammals
Microcirculation
Microsomes
Microwaves
    RT Diathermy
MINA 306-44-5
    UF Isonitrosoacetone
    UF Monoisonitrosoacetone
    UF Propanol, 2-oxo-1-oxime
    UF Propanone 1-oxime
   UF Pyruvaldehyde 1-oxime
Mipafox
            371-86-8
    UF N, N'-bis (1-methylethyl)phosphorodiamidic
    fluoride
    UF N,N<sup>*</sup>-diisopropylphosphorodiamidic fluoride
    UF Phosphorodiamidic fluoride, N,N-bis (1
    methylethyl)-
Mitochondria
```

49

Ē

Mitosis

Mitosis 51026-61-0 MMB-4 UF Pyridinium, 1,1'-Methylenebis-4 [hydroxyimino)methyI]-, dichloride Monkey, Rhesus BT Monkeys UF Macaca Mulatta Monkeys BT Laboratory animals NT Monkey, Rhesus Monobutylphosphoric acid U Butyl dihydrogen phosphate Monocrotophos BT Insecticides, organophosphate Monoisonitrosoacetone U MINA Monopotassium oxalate U Potassium acid oxalate Morphine 57-27-2 Morpholinium, 2,2'-[1,1'-biphenyl] 4,4'-diylbis [2 hydroxy-4,4-dimethyl-U Hemicholinium Morpholinium, 2,2'[1,1-biphenyl]-4,4'-diylbis [2 hydroxy-4,4-dimethyl-, dibromide-U HC-3 Morpholinium, 2,2' [1,1'-biphenyl]4,4'-diylbis [2 hydroxy-4,4-dimethyl-, dibromide U Hemicholinium-3 Morphothion 144-41-2 Mortality UF Death rate Motor activity Motor endplate U Neuromuscular junction Motor neurons BT Neurons Mouth I1PA U Phosphonic acid, methyl-MSF U Methanesulfonic fluoride Mucus Muscaranic action Muscarinic agents U Parasympathomimetics Muscarinic receptors U Receptors, muscarinic Muscle contraction RT Muscle relaxation Muscle denervation

Muscle relaxants, central

1.

Muscle relaxants, central Muscle relaxation RT Muscle contraction

Muscle rigidity Muscles General term. See Table of Muscles for specific names. NT Gastrocnemius muscle NT Pectoralis muscles NT Tibial muscle Muscle, smooth Muscle spasticity UF Spasticity, muscle Musculoskeletal system Mustard Mustard gas U 2,2'-Dichloroethyl sulfide Mutagens RT Mutation RT Teratogenic agents Mutation

RT Mutagens Myocardial depressants U Anti-arrhythmia agents Myoclonus Myoneural junction U Neuromuscular junction

.

٦...

NAIL

Nails Naled BT Insecticides, organophosphate Naphtha BT Benzin 1-Naphthalenol, methylcarbamate U N-Methyl carbamate Beta-Naphthol acetate U Beta-Naphthyl acetate Naphthols 2-Naphthyl acetate U Beta-Naphthyl acetate Beta-Naphthyl acetate 1523-11-1 UF 2-Acetoxynaphthalene UF 2-Naphthyl acetate UF Beta-Naphthol acetate UF O-Acetyl-beta-maphthol Neck Neoserine methyl sulfate U Neostigmine methyl sulfate 59-99-4 Neostigmine UF Benzenaminium, 3-[[(dimethylamino) carbonyl]oxy] N, N, N-trimethyl-**UF** Prostigmin **UF** Prostigmine Neostigmine bromide 114-80-7 UF Prostigmin bromide UF Prostigmine bromide Neostigmine methyl sulfate 51-60-5 59954-03-9 UF Neoserine methyl sulfate UF Prostigmine methyl sulfate Nerve block Nerve cells U Neurons Nerve degeneration UF Neuron degeneration UF Retrograde degeneration Nerve endings NT Neuroeffector junction NT Prressorreceptors NT Receptors, sensory NT Thermoreceptors RT Neural transmission Nerve endings, sensory U Receptors, sensory Nerve fibers NT Axons Nerve gases Nerve-muscle preparation U Neuromuscular junction Nerve net U Nervous system

52

1.

and the second state of th

53

Nerve regeneration Nerves NT Tibial nerve NT Vagus nerve Nerve stimulation Nerve tissue Nerve transmission U Neural transmission Nerve transmitter substances U Neuroregulators Nervous system NT Autonomic nervous system NT Central nervous system UF Nerve net Nervous system diseases RT Neurology Nervous system physiology Neural conduction Conduction along a single nerve, as opposed to neural transmission (between neurons) RT Neurons UF Nerve conduction Neuralgia Neural inhibition UF Inhibition, neural Neural pathways Neural transmission RT Nerve endings Transmission between nerves, as opposed to neural conduction (along a single nerve) UF Nerve transmission Neuritis Neuroblast Neuroblastoma Neurochemistry Neuroeffector junction BT Nerve endings Neurofibrils BT Neurons Neurohumors U Neuroregulators Neuroleptics U Tranquilizing agents, major Neurologic examination Neurologic manifestations Neurology RT Nervous system diseases Neuromodulators U Neuroregulators Neuromuscular agents Neuromuscular blocking agents Neuromuscular diseases

Nerve regeneration

Neuromuscular paralysis Neuromuscular spindles Neuromuscular transmission Neuromusicular agents Neuron degeneration U Nerve degeneration Neurons NT Autonimic fibers NT Axons NT Dendrites NT Interneurons NT Motor neurons NT Neurofibrils NT Neurons, afferent NT Neurons, efferent NT Synapses RT Neural conduction UF Nerve cells Neurons, afferent BT Neurons UF Neurons, sensory Neurons, efferent BT Neurons Neurons, sensory U Neurons, afferent Neuropathy Neurophysiology RT Sensation Neuroreceptors U Receptors, sensory Neuroregulators UF Nerve transmitter substances UF Neurohumors UF Neuromodulators UF Neurotransmitters Neurosecretion Neurosurgery Neurotendinous spindles Neurotoxins Neurotransmitters U Neuroregulators Niacin U Nicotinic acid

Neuromuscular functions

Neuromuscular functions Neuromuscular junction

> UF Motor endplate UF Myoneural junction

UF Nerve-muscle preparation

-

1

.

54

55

1:

54-11-5 Nicotine Nicotinic acid 59-67-6 UF 3-Pyridinecarboxylic acid **UF** Niacin Nicotinic acid 1-oxide U Oxiniacic acid Nicotinic agents U Ganglionic stimulants Nicotinic receptors U Receptors, nicotinic 5657-61-4 Nicotinohydroxamic acid UF 3-Pyridinecarboxamide, N-hydroxy-Nictitating membrane RT Eyelids Niter U Sodium nitrate Nitrazepam 146-22-5 UF 1,3-Dihydro-7-nitro-5-phenyl-2H-1,4benzodiazepin-2-one UF 2H-1,4-Benzodiazepin-2-one, 1,3,dihydro-7-nitro 5-phenyl-UF Benzalin UF LA-1 UF Nitrodiazepam Nitric acid, sodium salt U Sodium nitrate Nitrodiazepam U Nitrazepam 7727-37-9 Nitrogen RT Amino compounds Nitrogen oxide U Nitrous oxide p-Nitrophenyl ethyl pentylphosphonate 3015-75-6 1-Nitropropane 108-03-2 Nitrostigmine U Parathion Nitrous oxide 10024-97-2 UF Dinitrogen monoxide UF Nitrogen axide NMR U Nuclear magnetic resonance NMR spectra U Nuclear magnetic resonance spectra Noradrenaline U Norepinephrine Norepinephrine 51-41-2 UF Arterenol UF Me thylnorepinephrine UF Noradrenaline Nose

Nuclear magnetic resonance

Nuclear magnetic resonance UF NMR Nuclear magnetic resonance spectra UF NMR spectra Nucleophiles Specific headings are used for specific nucleophiles. Nucleosides NT Adenosine Nucleotides Nucleotides, cyclic UF Cyclic nucleotides OAB U 3-Diethylaminooropyl oximinoacetate Obidoxime UF Toxoganin Obidoxime chloride U Toxogonin Obidoxime hydrochloride U Toxogonin Occiput Octamethyldiphosphoramide U Octamethyl pyrophosphoramide Octamethyl pyrophosphoramide 152-16-9 UF Diphosphoramide, octamethyl-UF Octamethyldiphosphoramide UF OMPA UF Sytam Oligomycin B 11050-94-5 BT Oligomycins Oligomycins NT Oligomycin B Olive oil OMPA U Octamethyl pyrophosphoramide Optical rotation Organophosphate poisoning Organophosphates U Organophosphorus compounds Organophosphorus compounds NT Aminoethylphosphonic acid NT Armin NT Phosphonoacetic acid NT Phosphoric acid, esters NT Pyrophosphoric acid, esters NT Sarin NT Soman RT Insecticides. Organophosphate UF Organophosphates UF Phosphates, organic

۰.

. .

7

÷.

1.

Ĩ

ţ

56

57 Organothiophosphorus compounds NT Insecticides, organothiophosphate Orthophosphoric acic U Phosphoric Acid Oscillometry Oscilloscope UF Cathode ray oscilloscope UF CRO Ouabain 630-60-4 UF Acocantherin UF G-Strophanthin Oxalates Oximes NT Toxogonin UF Hydroxyimino compounds Oximes, di-**U** Dioximes 3-Oximino-2-pentanone 609-29-0 Oxiniacic acid 2398-81-4 UF 3-Carboxypyridine N-oxide UF Nicotinic acid 1-oxide Oxotremorine 70-22-4 UF 2-pyrrolidinone, 1-[4-/1-Pyrrolidinyl]-2-butynyl]-N, N'-Oxydimethylene-bis (pyridinium-2-aldoxime-3-carboxamido) U HS-6 1, l'-Oxydimethylene bis-(4-tert)-butylpyridinium chloride U SAD-128 7782-44-7 Oxygen Oxygenation Oxygen consumption Oxygen deficiency U Anoxia Oxyparathion U Paraoxon 32p A beta-emitting radioactive phosphorus isotope UF Phosphorus-32 P2S 154-97-2 51729-73-8 UF 1-Methylpyridinium-2-aldoxime methanesulfonate UF 2-Hydroxyiminomethyl-1-methylpyridinium methanesulfonate UF 2-PAM methanesulfonate UF N-Methylpyridinium-2-aldoxime methane sulfonate UF Pralidoxime mesylate UF Pralidoxime methanesulfonate UF Pyridine-2-aldoxime methyl methanesulfonate UF Pyridinium, 2-[(hydroxyimino)methyl]-1-methyl-, methanesulfonate (salt) Pain

. .

- -

. .

1.

1.

Pain (cont'd) RT Analgesia 94-63-3 PAM UF 2-PAM UF 2-FAM iodide UF 2-Pyridine aldoxime methyl iodide UF 2-Pyridinium aldoxime methochloride UF Pralidoxime iodide UF Pralidoxime methiodide UF Pyridinium, 2-E (hydroxyimino) methyl]-1- methyl-. iodide 2-PAM U PAM 51-15-0 27951-78-6 2-PAM chloride UF 1-Methyl-2-aldoximinopyridinium chloride UF 2-Pyridinealdoxime methochloride UF Pralidoxime chloride 2-PAM iocide U PAM 2-PAM methanesulfonate U P2S Pancreas RT Exocrine glands Pancreas, endocrine U Islands of Langerhans Pancreatic ducts Paper chromatography U Chromatography, paper Paper electrophoresis Paralysis Paradxon 311-45-5 **U** Parathion UF Diethyl-p-nitrophenyl phosphate UF E-600 UF Ethyl paraoxon UF Oxyparathion UF Phosphacol UF Phosphoric acid, esters, diethyl-4-nitrophenyl ester Parasympathetic ganglia U Ganglia, parasympathetic Parasympathetic nervous system Parasympatholotics NT Caramiphen hydrochloride Parasympatholytics NT Benactyzine NT Carbachol UF Anticholinergic agents UF Antimuscarinic agents UF Cholinergic blocking agents UF Cholinolytics Parasympathomimetics

Pain

• •

- -

ľ

Parasympathomimetics

Parasympathomimetics (cont'd) NT Atropine UF Cholinergic agents UF Cholinomimetics UF Muscarinic agents Parathion 56-38-2 UF AATP UF Diethyl p-nitrophenyl phosphorothionate UF Diethyl p-nitrophenylthionophosphate UF Diethyl p-nitrophenylthiophosphate UF Ethyl parathion UF Nicrostigmine UF Paraoxon UF Phosphorothioic acid, esters, 0,0-diethyl 0-(4 nitrophenyl) ester UF Thiophes Parathoid glands BT Endocrine glands Parpanil U Caramiphen Parpanit U Caramiphen hydrochloride Pathology NT Histopathology Pectoralis muscles BT Muscles Pelvis Pentaphen U Caramiphen Pentaphene hydrochloride U Caramiphen hydrochloride 76-74-4 Pentobarbital UF Pentobarbitone Pentobarbital sodium 57-33-0 UF Pentobarbitone sodium UF Sodium 5-ethyl-5-(1-Methylbutyl) barbiturate UF Sodium pentobarbital UF Sodium pentobarbitone Pentobarbitone sodium U Pentobarbital sodium Peptide hydrolases BT Hydrolases NT Alpha-Chymotrypsin UF Proteolytic enzymes 7601-90-3 Perchloric acid Percutaneous absorption Perfusion Perfusion, regional Perineum Periodicity RT Circadian rhythm Peripheral nerves

59

. .

. .

• •

ς.

- -

I.

Ì

Permeability

Permeability Permeability, cell membrane U Cell membrane permeability Pesticides Petroleum ether BT Benzin U Ligroin pH RT Acidity Phencapton U Phenkapton Phenkapton 2275-14-1 BT Phosphorodithioic acid, esters UF Phencapton UF Phenkaptone VF Phosphorodithioic acid, esters, S-CE(2,5) dichlorophenyl)thio]methyl]0,0-diethyl ester Phenkaptone U Phenkapton 50-06-6 Phenobarbital 10H-Phenothiazine, 10[(diethylamino)-acetyl] U Difazin 10H-Phenothiazine-10-propanamine, N, N-dimethy1-2-(trifluoromethyl)-U Triflupromazine Phenoxybenzamine U Dibenzyline Phenoxybenzamine chloride U Dibenzyline hydrochloride Phenoxybenzamine hydrochloride U Dibenzyline hydrochloride Phenyl acetate 122-79-2 UF Acetic acid phenyl ester UF Acetyl phenol alpha-Phenylbenzeneacetic acid 2-(diethylamino) ethyl ester U Trasentine hydrochloride Phenylhydrazine 100-63-0 UF Hydrazine, phenyl UF PHZ Phenyl saligenin phosphate 4081-23-6 UF Saligenin cyclic phenyl phosphate Phorate 298-02-2 BT Insecticides, organothiophosphate **U** Thimet Phosdrin 7786-34-7 UF Mevinphos UF 2-Butenoic acid, 3-E(dimethoxy-phosphinyl)oxy] methyl ester Phosgene 75-44-5 UF Carbonic dichloride UF Carbonyl chloride

Phosmet

Phosmet BT Insecticides, organothiophosphate Phosphacol U Paraoxon Phosphamide U Dimethoate Phosphamidon 13171-21-6 BT Insecticides, organophosphate Phosphatases BT Hydrolases NT Adenosine triphosphatase Phosphate esters U Phosphoric acid, esters Phosphates UF Phosphates, inorganic Phosphates, inorganic **U** Phosphates Phosphates, organic U Organophosphorus compounds Phosphatidylcholines U Lecithins UF Choline phosphoglycerides Phosphodiesterases NT Cyclic nucleotide phosphodiesterases Phospholine U Echothiophate Phospholine iodide U Echothiophate iddide Phospholipids Phosphonate U Phosphonic acid, ion(2-) Phosphonates Phosphonic acid 13598-36-2 868-85-9 Phosphonic acid, dimethyl ester UF Methyl phosphonate Phosphonic acid, ethyl-, ethyl 4-nitrophenyl ester U Armin Phosphonic acid, ion(2-) UF Phosphonate Phosphonic acid, methyl-UF Methylphosphonic acid UF MPA Phosphonoacetic acid BT Organophosphorus compounds 14939-29-8 Phosphonofluoridic acid Phosphonofluoridic acid, methyl-, 1-methylethyl ester U Sarin Phosphonofluoridic acid, methyl-, 1,2,2-trimethylpropyl ester U Soman 27682-26-4 Phosphonofluoridimidic acid Phosphonothioic acid, methyl-, O-ethyl ester

61

· Contraction -

Phosphonothioic acid, methyl-, 0-ethyl ester

Phosphonothioic acid, methyl-, 0-ethyl ester (cont'd) U GF-42 Phosphonothioic acid, methyl-, O-ethyl S-C2-(ethylthio) ethyll ester U GD-7 Phosphonothioic acid, methyl-, S-[2 [(dimethylamino)thiolethyl]O-ethyl ester . U Medemo Phosphonothioic acid, phenyl-O-ethyl O-(4 nitrophenyl)ester Equilibrium U EPN Phosphonylation Phosphoramidothioic acid, (1-methylethyl)-0-(2,4 dichlorophenyl)-O-methyl ester U DMPA (herbicide) Phosphoric acid 7664-38-2 UF Orthophosphoric acid Phosphoric acid, esters BT Organophosphorus compounds UF Phosphate esters Phosphoric acid, esters, 2,2-dichloroethenyl dimethyl ester U DDVP Phosphoric acid, esters, diethyl-4-nitrophenyl ester U Paraoxon Phosphoric acid, esters, ethyl ester UF Ethyl phosphoric acid Phosphoroamidocyanidic acid, dimethyl-, ethyl ester U Tabun Phosphorodiamide fluoride, tetramethyl-U Dimefox Phosphorodiamidic fluoride, N, N-bis (1-methylethyl)-U Mipafox Phosphorodithioic acid, esters NT Phenkapton Phosphorodithioic acid, esters, S-[[(2,5 dichlorophenyl)thio]methyl]0,0-diethyl ester U Phenkapton Phosphorodithionic acid, esters, 0,0-dimethyl S-E2 (methylamino)-2-oxoethyl] ester U Dimethoate Phosphorofluoridic acid, bis (1-methylethyl) ester U DFP (Pesticide) U Isoflurophate Phosphorothioic acid, 0,0-diethyl 0-(2-isopropyl-6 methyl-4-pyrimidinyl) ester U Diazinon

Phosphorothioic acid, esters, O, O-diethyl O-(4-nitrophenyl) ester U Parathion Phosphorothioic acid, esters, S-[2-(diethylamino)ethyl] O, O-diethyl ester **U** Amiton 7723-14-0 Phosphorus Phosphorus-32 U 32p Phosphorylase phosphatase Phosphorylation 107-73-3 Phosphorylcholine BT Choline UF Choline phosphate chloride Phosphorylthiocholines Phosvel BT Insecticides, organothiophosphate Phrenic nerve Physical stimulation UF Stimulation, physical 50975-37-6 Physostigmine 57-47-6 UF Eserine Physostigmine hydrochloride 6091-12-9 Physostigmine salicylate 57-64-7 Physostigmine sulfate 64-47-1 PHZ U Phenylhydrazine Pinacoloxymethylphosphoryl fluoride U Soman Pinacolyl alcohol 464-07-3 UF 2-Butanol, 3, 3-dimethyl-Pinacolyl hydrogen methylphosphonate U PMPA O-Pinacolyl hydrogen methylphosphonate U PMPA Pinacolyl methylfluorophosphonate U Soman O-Pinacolyl methylphosphonate U PMPA Pinacolyl methylphosphonic acid U PMPA Pinacolyl methylphosphonofluoridate U. Soman Pineal body BT Endocrine glands Piperazines NT DMPP Piperazinium, 1,1-dimethyl-4-phenyl-, iodide U DMPP

63

- -

۰.

ľ

Pituitary-adrenal system BT Endocrine glands Pituitary gland BT Endocrine glands Plasma UF Blood plasma Plasma membrane U Cell membrane Pleura PMCG 2001-91-4 UF N-Ethyl-2-pyrrolidylmethyl-phenyl cyclopentylglycolate hydrochloride PMFP U Soman PMPA 616-52-4 UF O-Pinacolyl hydrogen methylphosphonate UF O-Pinacolyl methylphosphonate UF Pinacolyl hydrogen methylphosphonate UF Pinacolyl methylphosphonic acid 32 P-PMPA UF ³²P-Pinacolyl methylphosphonic acid Poisoning RT Antidotes RT Poisons RT Toxicology Poisons RT Poisoning RT Toxicology Polyethyleneglycol octylphenol ether U Triton X-100 Ponalid U Ethylbenztropine Pons Potassium 7440-09-7 Potassium acid oxalate 127-95-7 UF Monopotassium oxalate UF Potassium hydrogen oxalate UF Potassium oxalate Potassium chloride 7447-40-7 Potassium fluoride 7789-23-3 Potassium hydrogen oxalate U Potassium acid oxalate Potassium iodide 7681-11-0 Potassium oxalate U Potassium acid oxalate Potassium persulfate 7727-21-1 Potency Potentiation Pralidoxime chloride

. .

- -

. .

L

Pralidoxime chloride (cont'd) U 2-PAM chloride Pralidoxime iodide U PAM Pralidoxime mesylate U P2S Pralidoxime methanesulfonate U P2S Pralidoxime methiodide U PAM Pressorreceptors BT Nerve endings Pressure RT Blood pressure RT Manometry RT Venous pressure Prilocaine 721-50-6 UF Propitocaine Primary irritancy **RT** Irritation Primates ST Mammals Procaine 59-46-1 UF Benzoic acid, 4-amino, 2-(diethylamino) ethyl ester Promazil U Chlorpromazine Promethium 7440-12-2 Radioactive, metallic chemical element, formerly called florentium and illinium 1-Propanaminium, 2-(acetyloxy)-N, N, N-trimethyl-U Methacholine 1-Propanaminium, 2-acetyloxy)-N, N, N-trimethyl-, bromide U Methacholine bromide 1-Propanaminium, 2(acetyloxy)-N, N, N-trimethyl-, chloride U Methacholine chloride 1,2-Propanediol U alpha-Propylene glycol 1, 3-Propanediol, 2-amino-2-'hydroxymethyl)-U Tris buffer Propanil 709-98-8 UF DPA 2-Propanol 67-63-0 UF Isopropanol UF Isopropyl alcohol 1-Propanol, 3-(diethylamino)-, diphenylacetate, hydrochloride U Arpenal Propanol, 2-oxo-l-oxime U MINA

65

ł

. .

1.

Propanone 1-oxime U MINA Propionylcholine 5072-54-8 Propionylcholine chloride 2365-13-1 5072-54-8 Propionylcholine iodide Propionylcholinesterase U Cholinesterase Propitocaine U Prilocaine alpha-Propylene glycol 57-55-6 UF 1,2-Propanediol UF Methyl glycol 504-63-2 beta-Propylene glycol Prostigmin U Neostigmine Prostigmin bromide U Neostigmine bromide Prostigmine **U** Neostigmine Prostigmine bromide U Neostigmine bromide Prostigmine methyl sulfate U Neostigmine methyl sulfate Protective doses Protective index Protective ratio Proteins General use only. Prefer specific proteins. Proteolytic enzymes U Peptide hydrolases Pseudocholinesterase U Cholinesterase Pulmonary alveoli BT Lung Pulse Purification Pyramat 2532-49-2 Pyridine 110-86-1 UF Pyridine ring 2-Pyridinealdoxime methochloride U 2-PAM chloride 2-Pyridine aldoxime methyl iodide U PAM Pyridine-2-aldoxime methyl methanesulfonate U P2S 3-Pyridinecarboxamide, N-hydroxy-U Nicotinohydroxamic acid 3-Pyridinecarboxylic acid

المين المحمد الم

3-Pyridinecarboxylic acid 3-Pyridinecarboxylic acid (cont'd) U Nicotinic acid Pyridine, compounds Pyridine methiodide U Methylpyridinium iodide Pyridine ring U Pyridine Pyridines Pyridinium, 1-[[[3-(aminocarbonyl) pyridinio]methoxy] U. HS-6 methyl] -2-[(hydroxyimino) methyl] -, dichloride Pyridinium, 1-CCC4 aminocarbonylpyridinio]methoxy]methyl] -2 [hydroxyimino)methyl]-dichloride U HI-6 Pyridinium, compounds Pyridinium, 3-CC (dimethylamino) carbonyl JoxyJ-1-methyl-U Pyridostigmine Pyridinium, 2-Chydroxyimino)methyl]-1- CCC4-[(hydroxyimino) methyl] pyridinio] methoxy] methyl], dichloride U HS-3 Pyridinium, 2-E (hydroxyimino) methyl]-1-methyl-, methanesulfonate (salt) U PZS Pyridinium, 2-[(hydroxyimino)methyl]-1- methyl-, iodide U PAM 2-Pyridinium aldoxime methochloride U PAM Pyridinium, 1,1'-Methylenebis-4-Chydroxyimino)methyl]-, dichloride U MMB-4 Pyridinium, 1,1' [oxybis(methylene bisi4 [(hydroxyimino) methyl]-dichloride U Toxogonin Pyridinium, 1,1' Coxybis(mmethylene)]bis[4-(1,1dimethylethyl)-, dichloride U SAD-128 Pyridinium, 1,1'-(1,3-propanediyl)bis [4 [(hydroxyimino)methyl]-,dibromide U TMB-4 Pyridostigmine 155-97-5 UF Pyridinium, 3-CE (dimethylamino) carbonyl Joxy 3-1 methyl-Pyridostigmine bromide 101-26-8 U Mestinon 2,4,6 (1H,3H,5H)-pyrimidinetrione, 5,5-diethyl-**U** Barbital 2,4,6 (1H,3H,5H)-Pyrimidinetrione,5,5 diethyl U Barbital Pyrolan 87-47-8

Pyrophosphoric acid, esters

....

Pyrophosphoric acid, esters BT Organophosphorus compounds Pyrophosphoric acid tetraethyl ester U Tetraethyl pyrophosphate 2-pyrrolidinone, 1-[4-(1-pyrrolidiny1)-2-butynyl]-U Oxotremorine Pyruvaldehyde 1-oxime U MINA Quaternary ammonium compounds 130-95-0 Quinine Quinclinium compounds Quinuclidines NT Quinuclidinyl benzilate NT Quinuclidinyl benzilate hydrochloride Quinuclidinyl benzilate BT Quinuclidines Quinuclidinyl benzilate hydrochloride 13004-56-3 BT Quinuclidines UF HNB-3 Rabbits BT Laboratory animals BT Mammals Radicals, acyl UF Acyl groups Radicals, alkoxy UF Alkoxy Radicals, alkyl UF Alkyl radical Radioactivity Radioautography U Autoradiography Radioimmunoassay Radiometry RT Geiger Counter Rare earth metals Rats BT Laboratory animals BT Mammals BT Tail Rat tail Reaction time UF Response time Reactivation Reactivity Receptors Receptors, cholinergic UF Cholinergic receptors UF Cholinoceptive sites UF Cholinoceptors Receptors, immunologic RT Immunity Receptors, muscarinic

Receptors, muscarinic (cont'd) UF Muscarinic receptors Receptors, nicotinic UF Nicotinic receptors Receptors, sensory BT Nerve endings UF Neuroreceptors Red blood cells U Erythrocytes Renal artery Renal damage Renal veins

Research design

UF Experimental design Resistance Respiration NT Aspiration RT Apnea RT Lung Respiration, artificial UF Artificial respiration UF Artificial ventilation UF Ventilation, mechanical

Respiration disorders Respirators UF Ventilators, pulmonary Respiratory air flow NT Maximal voluntary ventilation Respiratory center Respiratory depression Respiratory failure U Respiratory insufficiency

۰.

Respiratory function tests Respiratory insufficiency

UF Respiratory failure Respiratory paralysis Respiratory system Response time U RJaction time Reticulocytes RT Erythrocytes Retina Retrograde degeneration U Nerve degeneration Ribonucleic acids U RNA

69

. .

. .

1.

1.

الرباد فليقو للمحصص الألاديان

RNA

RNA

1.

Ţ

```
UF Ribonucleic acids
RNA, Messenger
RNA, Transfer
Ro-3-0340
           5823-10-9
Ro-2-3308
           6581-06-2
SAD-128
            40225-02-3
    UF 1,1'-Oxydimethylene bis-(4-tert)-butylpyridinium
    chloride
Saligenin cyclic phenyl phosphate
    U Phenyl saligenin phosphate
Saline
    U Sodium chloride
Sarin 107-44-8
    BT Organophosphorus compounds
    UF Isopropoxymethylphosphoryl fluoride
    UF Isopropyl methyl fluorophosphonate
    UF Isopropyl methyl phosphonofluoridate
    UF Methyl isopropoxy phosphoryl fluoride
    UF Methylphosphonofluoridic acid, 1-methylethyl
    ester
    UF Phosphonofluoridic acid, methyl-, 1-methylethyl
    ester
32P-Sarin
Sciatic nerve
Scintillation counting
Scopolamine 51-34-3
    UF Hyoscine
Scopolamine hydrobromide
                              114-49-8
Scopolamine methyl bromide
    U Methylscopolamine
    U Methylscopolamine bromide
SD 1652
    U 2,2-dichlorovinyl diethyl phosphate
Seawater, artificial
Sebaceous glands
Secretions
Sedatives
    U Hypnotics and Sedatives
Sedatives, Nonbarbiturate
    BT Hypnotics and Sedatives
Seizures
Sensation
    RT Neurophysiology
Sense organs
    NT Ear
    NT Eye
Sensitization
```

•

Sensitization (cont'd) **RT** Hypersensitivity Serine 6898-95-9 UF 2-Amino-3-hydroxypropionic acid UF Beta-Hydroxylalanine L-Serine 56-45-1 Serum Serum albumin Serum albumin, bovine UF Bovine serum albumin Sevin U N-Methyl carbamate Sheep Shoulder Skin Skin absorption UF Absorption, skin UF Dermal absorption Skin, animal Skull RT Intracranial pressure Soda niter J Sodium nitrate 7440-23-5 Sodium Sodium amobarbital U Amobarbital sodium Sodium amytal U Amobarbital sodium 26628-22-8 Sodium azile 144-55-8 Sodium bicarbonate UF Carbonic acid, monosodium salt Sodium chloride 7647-14-5 UF Saline Sodium 5-ethyl-5-/1-Methylbutyl) barbiturate U Pentobarbital sodium Sodium fluoride 7681-49-4 Sodium hexobarbital U Hexobarbital sodium Sodium hexobarbitone U Hexobarbital sodium Sodium hydroxide 1310-73-2 Sodium hyposulfite U Sodium thiosulfate 7631-99-4 Sodium nitrate UF Niter UF Nitric acid, sodium salt UF Soda niter Sodium pentobarbital U Pentobarbital sodium Sodium pentobarbitone U Pentobarbital sodium Sodium pentothal

71

Sodium pentothal (cont'd) U Thiopental sodium Sodium pentothiobarbital U Thiopental sodium 7558-79-4 Sodium phosphate (dibasic) 7558-80-7 Sodium phosphate (monobasic) Sodium thiopental U Thiopental sodium Sodium thiopentone U Thiopental sodium 7772-98-7 Sodium thiosulfate UF Disodium thiosulfate UF Hypo UF Sodium hyposulfite UF Thiosulfuric acid, disodium salt Solvents 96-64-0 Soman BT Organophosphorus compounds UF 1,1,2-Trimethylpropoxyfluorophosphine oxide UF 1 2,2-Trimethylpropyl-methylphosphonofluoridate UF 3,3-Dimethyl-2-butyl-methyl-phosphonofluoridate UF Fluoromethyl/1, 2, 2-trimethylpropoxy) phosphine oxide UF Methyl pinacolyl phosphonofluoridate UF Methyl pinacolyloxy phosphoryl flouride UF Methylphosphonofluoridic acid 1, 2, 2-trimethyl propyl ester UF Methylphosphonofluoridic acid 1, 2, 2-trimethylpropyl ester UF Phosphonofluoridic acid, methyl-, 1,2,2-trimethylpropyl ester UF Pinacoloxymethylphosphoryl fluoride UF Pinacolyl methylfluoriphosphonate UF Pinacolyl methylphosphonofluoridate UF PMFP UF Zoman 32p-Soman Soman poisoning Sonication Spasticity, muscle U Muscle spasticity Spectra NT Ultraviolet and Visible spectra Spectrometry UF Spectrophotometry Spectrophotometry U Spectrometry Spheroidine U Tetrodotoxin Sphingomyelins

1

1

1.

l

1

72

Spinal cord Spinal nerve roots NT Ganglia, spinal Spinal nerves Spine Spleen Squid Stereoisomerism and Stereoisomers U Isomerism and Isomers Stimulation, chemical Stimulation, electric U Electric stimulation Stimulation, physical U Physical stimulation Stoichiometry Stomach BT Gastrointestinal system Stratum corneum Substrate Succinate dehydrogenase UF Succinic oxidase Succinic oxidase U Succinate dehydrogenase Sulfides ' U Thioethers Sulfonium, [2-[(ethoxymethylphosphinyl) thio] ethyl]ethylmethyl-, methyl sulfate U GD-42 Sulfonyl compounds 7704-34-9 Sulfur Sweat glands NT Apocrine glands NT Eccrine glands Sympathetic blocking agents U Sympatholytics Sympathetic ganglia U Ganglia, sympathetic Sympathetic nervous system Sympatholytics UF Sympathetic blocking agents Synapses BT Neurons Synaptic activity Synaptic receptors Synaptic vesicles Synergism Sytam Octamethyl pyrophosphoramide

73

Tabun 77-81-6 UF Dimethylamidoethoxyphosphoryl cyanide UF Dimethylphosphoramidocyanidic acid. ethyl ester UF Ethyl dimethylamidocyanophosphate UF Ethyl dimethylphosphoramidocyanidate UF Ethyl N, N-dimethyl phosphoramido cyanidate UF N-Dimethylphosphoramidocyanidate UF Phosphoramidocyanidic acid, dimethyl-, ethyl ester Tabunase 9032-18-2 UF Diisopropylphosphorofluoridase Tachycardia Tachyphylaxis Tachypnea 321-64-2 Tacrine UF 1, 2, 3, 4-tetrahydro-5-aminoacridine UF 1,2,3,4-Tetrahydro-9-acridinamine UF 9-Acridinamine, 1, 2, 3, 4-tetrahydro-UF 9-Amino-1, 2, 3, 4-tet: ahydroacridine Tail Tail response Tarichatoxin U Tetrodotoxin TCA U Trichloroacetic acid 3570-55-6 TDT UF 2,2'-thiodiethanethiol UF 2-Mercaptoethyl sulfide Temperature RT Body temperature RT Thermometers Tendons Tensilon 116-38-1 UF Benzenaminium, N-ethyl-3-hydroxy-N, N-dimethyl-, chloridc Tensilon bromide U Edrophonium bromide Tensilon chloride U Edrophonium chloride TEP U Tetraethyl pyrophosphate TEPP U Tetraethyl pyrophosphate Teratogenic agents RT Mutagens Tetanic activity Tetanic blockade Tetanic contraction Tetanic response Tetanic stimulation Tetanus Tetraethyldiphosphate U Tetraethyl pyrophosphate Tetraethyl pyrophosphate 107-49-3 UF Diphosphoric acid tetraethyl ester

1

-

Tetraethyl pyrophosphate (cont'd) UF Pyrophosphoric acid tetraethyl ester UF TEP UF TEPP UF Tetraethyldiphosphate UF Tetrastigmine UF Tetron-100 1, 2, 3, 4-Tetrahydro-9-acridinamine U Tacrine 1, 2, 3, 4-tetrahydro-5-aminoacridine U Tacrine Tetraisopropyl pyrophosphoramide Ũ DPDA Tetram U Amiton N, 2, 3, 3-Tetramethylbichclo [2. 2. 1] heptan-2-amine U Mecamylamine Tetrastigmine U Tetraethyl pyrophosphate Tetrodontoxin U Tetrodotoxin Tetrodotoxin 4368-28-9 UF Speroidine UF Tarichatoxin UF Tetrodontoxin UF TTX Tetron-100 U Tetraethyl pyrophosphate THA Thalactamine Ũ Thalactamin U Thalactamine Thalactamine 23434-97-1 UF THA UF Thalactamin Thalamus Tham U Tris buffer Theramine U Histamine Therapeutic processes Therapy Thermography RT Body temperature

۶,

- -

. .

F

1

Ī

I

an an an an an **Alama**tan a

Thermometers RT Body temperature RT Temperature Thermoreceptors BT Nerve endings Thermoregulation Body temperature regulation U Thigh Thimet U Phorate Thin-layer chromatography U Chromatography, thin-layer 625-00-3 Thiocholine BT Choline UF Ethanaminium, 2-mercapto-N, N, N-trimethyl-2, 2'-thiodiethanethiol TDT U Thioethers U Sulfides Thiometon BT Insecticides, organothiophosphate Thiopental sodium 71-73-8 7438-31-5 UF Sodium pentothal UF Sodium pentothiobarbital UF Sodium thiopental UF Sodium thiopentone UF Thiopentone sodium Thiopentone sodium U Thiopental sodium Thiophos **U** Parathion Thiosulfuric acid, disodium salt U Sodium thiosulfate Thiourea 62-56-6 Thorax Thorazine U Chlorpromazine 50-89-5 Thymidine UF 1-(2-Deoxy-beta-D-ribofuranosyl)-5-methyluracil UF Thymine-2-desoxyriboside Thymidine, esters Thymine-2-desoxyriboside U Thymidine Thyroid gland BT Endocrine glands Tibia Tibial muscle BT Muscles Ti bial nerve BT Nerves Tissue TMB-4 56-97-3 BT Oximes

. .

. .

ţ

.

E

•••••

~

The distance

56-97-3 (cont'd) TMB-4 UF Trimedoxime bromide UF 1.1'-Trimethylene-bis(4-formylpyridinium bromide) TOCP U Tri-o-tolyl phosphate 108-88-3 Toluene UF Benzene, methyl-TOTP Tri-o-tolyl phosphate U Toxicity Toxicology **RT** Poisoning RT Poisons Toxins Toxogonin 114-90-0 BT Oximes UF bis(4-hydroxyiminomethyl-pyridinium-l-methyl)-ether dichloride UF LuH-6 UF Obidoxime chloride UF Obidoxime hydrochloride UF Toxogonin dichloride UF Toxogonine Toxogonin dichloride U Toxogonin Toxogonine U Toxogonin Toxoids Trachea Tracheal cannula T ranguilizers U Tranquilizing agents Tranquilizing agents **RT** Hypnotics and Sedatives UF Tranquilizers Tranquilizing agents, major . UF Neuroleptics Tranquilizing agents, minor Transfusion U Blood transfusion Trasentine 64-95-9 50-42-0 Trasentine hydrochloride UF Adiphenine hydrochloride UF 2-Diethylaminoethyl diphenyl acetate hydrochloride UF Difacil hydrochloride 71 - 96 - 5Trazentine Tremor Trichlorfon 52-68-6 **UF** Dipterex Trichloroacetic acid 76-03-0 UF TCA

۰.

. .

4

Sections -



Tri-o-cresyl phosphate U Tri-o-tolyl phosphate Triethylcholine BT Choline Triflupromazine 146-54-3 Trimedoxime bromide U TMB-4 1, l'-Trimethylene-bis'4-formylpyridinium bromide) U TMB-4 1, l'-Trimethylene-bis(4-formylpyridinium) dioxime dibromide 56-97-2 Trimethylolaminomethane U Tris buffer 1, 1, 2-Trimethylpropoxyfluorophosphine oxide U Soman 1, 2, 2-Trimethylpropyl-methylphosphonofluoridate U Soman 77-86-1 Tris buffer UF 1, 3-Propanediol, 2-amino-2-(hydroxymethyl)-UF THAM UF Trimethylolaminomethane UF Tris(hydroxymethyl) methanamine Tritium 10028-17-8 BT Hydrogen, isotopes of UF ³H UF Hydrogen-3 Tri-o-tolyl phosphate 78-30-8 UF TOCP UF TOTP UF Tri-o-cresyl phosphate UF Tris (o-methylphenyl) phosphate Tritons Triton X-100 39409-11-5 66057-68-9 66057-69-0 9002-93-1 9010-42-8 9010-43-9 9077-65-0 UF Polyethyleneglycol octylphenol ether Tropaic acid U Tropic acid Tropic acid 529-64-6 UF alpha- (Hydroxymethyl) benzeneacetic acid UF Tropaic acid Trypan blue 72-57-1 Trypsin UF Tryptar Tryptar U Trypsin TTX U Tetrodotoxin Tubadil U d-Tubocurarine chloride

78

a statestate for

Tubarine U d-Tubocurarine chloride d-Tubocurarine 57-95-4 d-Tubocurarine chloride 57-94-3 UF Delacurarine UF Tubadil UF Tubarine Twitch Twitch response Twitch stimuli U-23223 U Benzoic acid, 3-chloro-2, 5, 6-trimethyl-UDP Uridine 5'-(trihydrogen diphosphate) U Ultraviolet and Visible spectra BT Spectra UF Ultraviolet spectra Ultraviolet rays Ultraviolet spectra U Ultraviolet and Visible spectra Urea 57-13-6 UF Carbamide UF Carbonyldiamide UF Ureaphil Ureaphil U Urea Urethan U Carbamic acid, esters, ethyl ester Urethane U Carbamic acid, esters, ethyl ester Urethanes For specific urethanes, see specific terms Uridine 5'-pyrophosphate U Uridine 5'=(trihydrogen diphosphate) Uridine 5-pyrophosphoric acid U Uridine 5'-(trihydrogen diphosphate) Uridine 5'-(tetrahydrogen triphosphate) U Uridine 5'-triphosphate Uridine 5'-(trihydrogen diphosphate) 58-98-0 UF UDP UF Uridine 5'-pyrophosphate UF Uridine 5-pyrophosphoric acid Uridine 5'-triphosphate 63-39-8 UF Uridine 5'-(tetrahydrogen triphosphate) UF UTP Urinary tract NT Bladder NT Kidney

79

- - -

ŧ

1.

Urogenital system UTP U Uridine 5'-triphosphate Vagus nerve BT Nerves Valium U Diazepam Vascular resistance Vasoconstriction Vasoconstriction agents UF Vasopressor agents Vasodilation Vasodilator agents Vasomotor system Vasopressor agents **U** Vasoconstriction agents Vein eins BT Blood vessels Venous pressure RT Pressure UF Blood pressure, venous Ventilation Term is used for environment, not lungs. Ventilation, artificial U Respiration, artificial Ventilation, mechanical U Respiration, artificial Ventilators, pulmonary **U** Respirators Veratrine U Cevadine Veronal U Barbital Vertebrates NT Mammals Vidine U Choline 865-21-4 Vinblastine UF Vincaleukoblastine UF VLB Vinblastine sulfate 145-67-9 UF Vincaleukoblastine, sulfate Vincaleukoblastine **U** Vinblastine Vincaleukoblastine, sulfate U Vinblastine sulfate

an an an the second second

Versamine U Mecamylamine

VLB U Vinblastine 51848-47-6 VX UF Ethyl-S-(2-diisopropylaminoethyl) methylthiophosphonate VX-3 Warburg technique Weight gain RT Body weight Weight loss RT Body weight White blood cells U Leukocytes Xylocaine U Lidocaine Yttrium Zoman U Soman Zytron U DMPA (herbicide)

•••

1

F

1.

[]

marine and and and a

1